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 Abstract  
This dissertation focuses on the preventive maintenance decision modeling in healthcare and 
service systems. In the first part of this dissertation, some issues in preventive health decisions 
for breast cancer are addressed, and in the second part, the required characteristics for preventive 
maintenance of an unreliable queuing system are derived.  
Adherence to cancer screening is the first issue that is addressed in this dissertation. Women’s 
adherence or compliance with mammography screening remained low in the recent years. In this 
dissertation, we first develop a design-based logistic regression model to quantify the probability 
of adherence to screening schedules based on women’s characteristics. In Chapter 3, we develop 
a randomized finite-horizon partially observable Markov chain to evaluate and compare different 
mammography screening strategies for women with different adherence behaviors in terms of 
quality adjusted life years (QALYs) and lifetime breast cancer mortality risk. The results imply 
that for the general population, the American Cancer Society (ACS) policy is an efficient frontier 
policy. In Chapter 4, the problem of overdiagnosis in cancer screening is addressed. 
Overdiagnosis is a side effect of screening and is defined as the diagnosis of a disease that will 
never cause symptoms or death during a patient's lifetime. We develop a mathematical 
framework to quantify the lifetime overdiagnosis and mortality risk for different screening 
policies, and derive the (near) optimal policies with minimum overdiagnosis risk. 
In the second part, we consider an unreliable queuing system with servers stored in a shared 
stack. In such a system, servers have heterogeneous transient usage since servers on the top of 
the stack are more likely to be used. We develop a continuous-time Markov chain model to 
 derive the utilization and usage time of servers in the system. These quantities are critical for the 
decision maker for deriving a maintenance policy. 
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 Introduction: Preventive Maintenance in Healthcare and Service Systems 1
“Prevention is better than treatment.” This proverb has inspired much research in a wide range of 
areas such as health, service and manufacturing systems.  
For health systems, preventive healthcare, or preventive medicine, focuses on disease prevention 
and health maintenance. Preventive healthcare includes early diagnosis of disease, counseling, 
and other interventions to avert a health problem. The goal of preventive healthcare is to prevent 
health problems or identify and treat them early before their effect on the patient’s life is 
irreversible. Chronic diseases, such as heart diseases and cancers, are the causes for 7 in every 10 
deaths among Americans each year, and they account for 75% of the nation’s health spending [1]. 
These chronic diseases can be largely preventable through appropriate preventive care like 
screening tests. Screening tests can advance the time of disease detection and detect the disease 
at stages when it is more curable and the treatment works more effectively. For example, 
mammography screening can detect breast cancer 1.7 years before a woman can feel a lump in 
her breast [2], and ultimately it can reduce breast cancer mortality rate by 15% [3]. 
Preventive maintenance in manufacturing and service systems, on the other hand, focuses on the 
care and maintenance of equipment and facilities to keep them in a satisfactory operating 
condition and to prevent them from sudden failure. The goal of preventive maintenance is to 
avoid and/or mitigate the consequences of failure of equipment. Preventive maintenance can 
save overall cost by decreasing equipment downtime, increasing life expectancy and efficiency 
of the equipment, enhancing customers’ satisfaction in service-oriented systems, etc. 
The focus of this dissertation is on the preventive care modeling in two areas: health systems and 
service-oriented systems. The former addresses the problem of preventive healthcare decisions 
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for chronic diseases with a focus on breast cancer, while the latter part provides insight on 
preventive maintenance of a service system with unreliable servers. Specifically, in the first part, 
we focus on the evaluation and optimization of preventive healthcare decisions which includes 
analysis and estimation of individual adherence behavior to preventive care, as well as the 
evaluation and optimization of cancer screening policies in terms of different patient outcomes. 
The following breast cancer screening issues are addressed: (1) characterizing the factors 
associated with patient’s adherence to mammography screening recommendations and 
estimating the probability of patient adherence to a prescribed screening test, (2) evaluating and 
comparing various screening mammography policies while incorporating heterogeneity in 
women’s adherence behaviors, and (3) minimizing overdiagnosis in cancer screening under 
various sources of uncertainty such as disease progression and efficacy of mammography tests. 
In the second part of this dissertation, an unreliable multi-server queuing system with stacked 
servers is studied. In such a system, the equipment/servers are used in a non-uniform fashion, i.e., 
servers on the top of the stack are more likely to be used in a finite time horizon than servers at 
the bottom. This implies that some servers deteriorate faster than the others. For such systems, an 
estimate of the transient utilization and usage time of servers can provide insight on deterioration 
patterns and preventive maintenance decisions.  
A more detailed outline of this dissertation is presented below. 
Chapter 2 addresses the problem of adherence to preventive mammography screening since the 
efficacy of mammography screening policies is strongly associated with women’s compliance 
with the recommendations. We developed a statistical model that characterizes significant factors 
associated with women’s adherence to mammography screening recommendations. The model is 
then used to estimate the probability that a woman complies with her physician’s 
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recommendation of undergoing a screening mammogram. The second chapter is the cornerstone 
for the next chapter since the results of this chapter serve as inputs for Chapter 3. 
In Chapter 3, we develop a randomized discrete-time finite-horizon partially observable Markov 
chain model to investigate the effect of imperfect adherence on the patients’ health outcomes for 
a wide range of screening mammography policies. The policies are evaluated in terms of the 
expected remaining quality adjusted life years (QALYs) and breast cancer lifetime mortality risk. 
Three possibilities for the cancer detection are considered in the proposed model: mammography 
screening detection, self-detection and interval cancer which represents fast growing cancers that 
show symptoms within 12 months following a negative mammogram. Various uncertainties such 
as breast cancer natural history, unreliability of mammography screening, interval cancer 
detection, and heterogeneity in patients’ adherence behaviors are incorporated into the proposed 
model.  
Chapter 4 addresses the overdiagnosis issue in cancer screening. Overdiagnosis is the major 
disadvantage of cancer screening and is defined as the diagnosis of screen-detected cancers that 
would not have presented clinically in a woman’s lifetime in the absence of screening [4]. In this 
chapter, a probabilistic model is developed to evaluate the overdiagnosis and cancer mortality 
risks of a screening schedule. Furthermore, we propose an optimization model to minimize the 
risk of overdignosis of preventive screening schedules while maintaining the patient’s lifetime 
breast cancer mortality risk at a predefined level. We incorporate uncertainty in disease onset, 
cancer sojourn time, and competing causes of death. 
Chapter 5 focuses on a service-oriented environment. In this chapter, an unreliable queueing 
system with  identical servers that are stored in a stack is studied. In such a queuing system, 
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customers may find it more convenient to select the server that is on the top of the stack. 
Similarly, customers finished with a server may find it more convenient to place the server back 
to the top of the stack. As a result, servers that begin at or near the top of the stack are used more 
frequently than the servers that are placed lower in the stack. In such a system, a server’s 
utilization is stochastically dependent on its initial location in the stack and the usage of the other 
servers.  In Chapter 5, we develop a continuous-time Markov chain model to estimate transient 
utilization and usage time of servers in such a system.  This study provides estimate on the 
deterioration behavior of servers which is critical information for the systems maintenance 
decisions. 
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 Analyzing Factors Associated with Women’s Attitudes and Behaviors Toward 2
Screening Mammography Using Design-Based Logistic Regression 
2.1 Introduction 
Breast cancer is the most common cancer worldwide in women contributing more than 25% of 
the total number of cancer cases diagnosed in 2012 [1]. It is also the most common non-skin 
cancer affecting women in the United States. According to the American Cancer Society, about 
one in eight US women will develop breast cancer in her lifetime. In 2015, an estimated 231,840 
invasive breast cancer cases will be diagnosed, and about 40,290 will die from breast cancer [2].  
Mammography plays an important role in detection of breast cancer when the cancer is in its 
early stage. It is known to be an effective method and the current standard practice for early 
diagnosis of breast cancer. On average, mammography can detect breast cancer 1.7 years before 
a woman can feel a lump in her breast [3]. In addition, it can reduce breast cancer mortality rate 
by a reasonable estimate of 15% [4].  
There are varying recommendations from different agencies for screening mammography in the 
U.S. The two most referred guidelines are from the American Cancer Society (ACS) and the U.S. 
Preventive Services Task Force (USPTF). The ACS recommends starting annual mammography 
at age 40 but recommends no ending age [5]. In November 2009 the USPSTF issued new breast 
cancer screening guidelines, which recommend biennial screening for women ages 50 to 74. The 
USPSTF also recommended that women ages 40 to 49 should not undergo screening 
mammography unless they are in a high-risk group [6]. 
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The impact of mammography on women’s outcomes is strongly associated with women’s 
compliance with the mammography recommendations. Examination of a clinic-based group of 
216 women with a strong family history of breast or ovarian cancer showed that 50%, 83%, 69%, 
and 53% of the women at age groups of 30–39, 40–49, 50–64, and 65 years and older, 
respectively, had only one mammogram between 1995 and 1999 [7]. More recently, a study by 
the Centers for Disease Control and Prevention (CDC) revealed that, in 2010 about 67.1% of 
women aged 40 and older had one mammogram between 2008 and 2010 [8]. 
In this study, we aim to (1) identify significant factors (socio-demographic, health-related, 
behavioral attributes and knowledge mammography) associated with women’s adherence to 
mammography screening, and (2) study the attitudes toward mammography in non-adherent 
women. We assume that women’s compliance with screening mammography is strongly 
correlated with their intentions to get a mammogram (i.e., their expectations about their next 
mammogram or their thoughts about getting a mammogram [9]). Based on this assumption, if a 
woman has a positive attitude toward screening mammograms and her plan for the next 
mammogram is within the next one or two years, then she is considered to be adherent.  
2.2 Methods 
2.2.1 Data Source 
We used the 2003 Health Information National Trends Survey (HINTS) data for this study [10]. 
HINTS, developed by the National Cancer Institute (NCI), is a nationally representative 
telephone survey of 6,369 adults aged 18 and older. The 2003 data is currently the only HINTS 
data that provides information on women’s attitudes and perceptions toward mammography. 
HINTS 2005 and 2007 data do not include questions regarding mammography. HINTS 2012 
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only reports the time of a most recent mammogram and whether a doctor has informed about a 
mammogram; however, no data is collected on women’s intentions or attitudes toward 
mammograms, which is the focus of this study.  
2.2.2 Study Design 
There are two stages for this study. In the first stage, we aim to identify significant factors 
associated with women’s adherence to mammography screenings. To be consistent with current 
mammography guidelines and practices, we focus on women older than 40. We perform the 
analyses separately for two age groups: women younger than 65, and women 65 and older. In 
contrast to earlier studies, we measure adherence based on women’s intentions and attitudes 
toward mammography.  
In the second stage, we focus only on women older than 42 with poor mammography history, i.e. 
women who have never had mammography or their most recent mammography was more than 
two years ago and they did not say "never heard of it" when asked why they had not had a 
mammogram. Age 42 is used as the lower boundary for these analyses because an every-other-
year interval for mammography requires enough time for women over age 40 to have a 
mammogram. We do not separate women younger and older than 65 in order to achieve an 
adequate sample size. We examine the differences between those who think about getting a 
mammogram and other women in this population. 
2.2.3 Predicting Factors 
We categorized factors that may be associated with women’s adherence to mammography 
screening into four groups: Socio-demographic characteristics including age, race, marital status, 
employment, education, income, health coverage, and living area based on Census Division; 
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Health-related characteristics including body mass index (BMI), average number of visits to a 
healthcare provider a year, family history of cancer, psychological distress composite score, 
being advised to have a mammogram, and having had a Pap smear; Behavioral characteristics 
including trusting cancer information from doctors, looking for cancer information, perception of 
chance of getting breast cancer, eating habits (consumption of fruits and vegetables), having 
exercised in the last month, and lifetime number of smoked cigarettes; Knowledge of breast 
cancer/mammography including knowing the age at which mammography should begin and the 
frequency of receiving mammograms. 
2.2.4 Statistical Analysis 
HINTS data includes a set of 50 replicate weights, which were generated according to jackknife 
variance estimation [10]. Data were weighted to produce overall and stratified estimates that 
represent the U.S. population. We incorporate weights in the analyses for the population study.  
To handle missing values for the predicting factors, we use the naive nearest neighbor hot deck 
method, which takes advantage of the similarity between the observations to impute the missing 
values. Each missing value is replaced with the observed response from the nearest observation 
in the data set [11]. The distance between two observations (x and y) is  
, 
 = ∑ , 
 , 2-1 
Where  is the number of the variables in the data set and  , 
 is 1 if  ≠ 
 and 0 if  = 
 . 
We defined adherence to mammography () separately for women aged 40 and 41 years versus 
those aged 42 and older, as a women aged 40 or 41 without any mammography history can still 
be considered adherent if she plans to get a mammogram in the near future (2 years or 1 year 
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respectively). We defined a woman older than 42 as adherent if the interval between her most 
recent self-reported mammogram and the next expected mammogram was less than two years. 
Otherwise she was considered non-adherent. We categorized those who answered the question 
“Do you have a plan to get mammography” with “undecided” or “not planned” as non-adherent. 
For this response variable, we built separate models and compared results between those less 
than 65 years and those age 65 and older. 
For the outcome of thinking about getting a mammogram in non-adherent women (τ), we narrow 
our attention to women who never had a mammogram or their most recent mammogram was 
more than two years ago. The response variable is one if the answer to the question “Have you 
thought about getting a mammogram” is yes, or zero otherwise.  
We examined bivariate associations between all potential independent variables to select 
significant covariates for inclusion in subsequent models. We used Rao-Scott corrections to chi-
squared tests to incorporate the survey design (50 jackknife weights) of the HINTS data.  
The standard logistic regression assumes that the data come from a simple random sample (i.e., 
independent and identically distributed (iid)). Thus, the standard logistic regression may be 
inappropriate for analyzing sample survey data due to clustering and stratification methods used 
in the survey designs [12]. Since the HINTS data are collected based on complicated multistage 
sampling designs, the classic methods for simple random sampling data may be inefficient for 
analyzing the HINTS data.  
Suppose that in the complex survey data collection, the population is separated into k strata 
( = 1, 2, … , ), with j primary sampling units (PSUs,  = 1, 2, . . . , ) in each stratum and i 
elements  = 1,2, … ,  in the !"PSU. Suppose the number of observations is: n =
11 
 
∑ ∑ n$%&'%($  where n$% is the number of elements from m$	primary sampling unit from stratum 
k. The pseudo-maximum likelihood function for the “design-based” logistic regression model is 
+++,-  × 
 / × ln,12 3/ + ,-  × 1 − 
 / × ln,1 − 12 3/,678
97
 
:
  2-2 
 
where w$%< is the known sampling weight for the kjith observation [13]. 
Design-based multiple logistic regression models [12-13] were developed to identify significant 
factors associated with (1) adherence to mammography and (2) thinking about getting a 
screening mammogram in non-adherent women. The design based multivariate logistic 
regression model for the logistic regression is 
=>	? = @ A 11 − 1B = C + D × EF +  ∗ HI +  ∗ JI + K ∗ JL&, 2-3 
 
where SD, HR, BR and KBC&M	are the vectors of socio-demographic, health related, behavior 
related and knowledge related features and C, D, , , R	K are the coefficients vectors of 
parameter estimates. 
We used the Wald tests [13] to determine the statistical significance of each coefficient in the 
model. Classification tables [13] are used to evaluate the performance of the logistic regression 
models. We considered a predicted value of 0.5 as the cut off point for our classification analyses. 
Suppose S  and TS  represent the predicted values from the regression models for adherence in 
women younger than 65 and women 65 and older, respectively. We consider a woman younger 
than 65 (65 and older) to be adherent if her probability to be adherent, S 	TS ,	is greater than 0.5 
and non-adherent otherwise. The same strategy is implemented for the outcome “thinking about 
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getting a mammogram” (? in non-adherent women.  The observed values for the dependent 
outcomes and the predicted values are then cross-classified to evaluate the predictive accuracy of 
the models. All analyses are performed at the significance level of 5%. 
2.3 Results 
The distributions of all predicting factors for the two response variables are presented in Table 2-
1. There are a total of 2,370 women included for the adherence to mammography response 
variable and 451 women included for the thinking about getting a mammogram response 
variable.   
2.3.1 Comparing mammography adherence among women in the two age groups 
The logistic regression results (Table 2-2) suggest that in the socio-demographic characteristics 
category, women who are single, separated, divorced or widowed are less likely to adhere to 
screening mammography compared to married women in both age groups (OR=0.685 and 
OR=0.499 for women younger than 65 and women aged 65 and older, respectively). As income 
increases, adherence to screening mammography also increases. Specifically among women 
younger than 65 the difference between women with income more than $75,000 and women 
whose income is less than $25,000 is significant (OR=2.526 for income greater than $75,000 
versus income less than $25,000). Women younger than 65 who have health insurance are also 
more likely to adhere to screening mammography (OR= 2.959).  
 
 
 Table  2-1 Distribution of socio-demographic, health related, behavioral, and knowledge related characteristics  
Independent Variables 
Women’s intentions and attitudes toward 
mammography 
Thinking about 
mammogram in non-
adherent women 
Age < 65 (N=1612)  Age ≥ 65 (N=758)   ∗ = 0 
(N=441) 
 =1 
(N=1171) 
T∗∗ = 0 
(N=265) 
T = 1 
(N=493) 
?ϯ = 0 
(N=199) 
? = 1 
(N=252) 
Socio-demographic characteristics 
Race 
Black 64 (14.51) 154 (13.15)  17 (6.41) 43 (8.72) 12 (6.03) 40 (15.87) 
White 284 (64.40) 914 (78.05)  199 (75.09) 420 (85.19) 14 (7.03) 16 (6.35) 
Other 36 (8.16) 53 (4.53)  11 (4.15) 10 (2.03) 160 (80.40) 183 (72.62) 
 Missing 57 (12.95) 50 (4.27)  38 (14.34) 20 (4.06) 13 (6.53) 13 (5.16) 
Marital status Married 200 (45.35) 726 (62.00)  45 (16.98) 197 (39.96) 56 (28.14) 115 (45.63) Single/Divorced/widowed 202 (45.80) 429 (36.63)  192 (72.45) 291 (59.03) 137 (68.84) 135 (53.57) 
 Missing 39 (8.84) 16 (1.36)  28 (10.56) 5 (1.01) 6 (3.01) 2 (0.79) 
Employment Employed 257 (58.28) 775 (66.18)  23 (8.68) 62 (12.58) 53 (26.63) 145 (57.54) Unemployed 144 (32.65) 383 (32.71)  214 (80.75) 424 (86.00) 141 (70.85) 102 (40.48) 
 Missing 40 (9.07) 13 (1.11)  28 (10.56) 7 (1.42) 5 (2.51)  5 (1.98) 
Education 
 
Some high school or less 65 (14.74) 94 (8.03)  68 (25.66) 73 (14.81) 45(22.61) 39 (15.48) 
High school Graduate 134 (30.38) 334 (28.52)  84 (32.70) 177 (35.90) 68 (34.17) 127 (50.40) 
Some college/College 
graduate 204 (46.26) 723 (61.74)  86 (32.45) 237 (48.07) 81 (40.70) 84 (33.33) 
 Missing 38 (8.62) 114 (9.73)  27 (10.19) 6 (1.22) 5 (2.51) 2 (0.79) 
Income 
≤ $25,000 146 (33.11) 249 (21.26)  147 (55.47) 204 (41.38) 106 (53.27) 100 (39.68) 
>$25,000 and ≤$75,000 161 (36.51) 543 (46.37)  50 (18.87) 178 (36.11) 50 (25.13) 94 (37.30) 
>$75,000 47 (10.66) 291 (24.85)  5 (1.89) 22 (4.06) 10 (5.02) 31 (12.30) 
 Missing 87 (19.73) 337 (28.78)  66 (23.77) 89 (18.05) 33 (16.58) 27 (10.71) 
Insurance No 107 (24.26) 79 (6.74)  4 (1.5) 2 (0.41) 31 (15.58) 46 (18.25) Yes 296 (67.12) 1071 (91.46)  232 (87.54) 487 (98.78) 161 (80.90) 204 (80.95) 
 Missing 38 (8.62) 21 (1.79)  29 (10.94) 4 (0.81) 7 (3.52) 2 (0.79) 
Living area based on 
Census Division 
East North Central 65 (14.74) 201 (17.16)  45 (16.98) 78 (15.82) 37 (18.59) 30 (11.90) 
East South Central 28 (6.35) 67 (5.72)  30 (11.32) 29 (5.88) 17 (8.54) 15 (5.95) 
Middle Atlantic 66 (14.97) 164 (14.00)  25 (9.43) 73 (14.81) 26 (13.06) 38 (15.08) 
Mountain 44 (9.97) 67 (5.72)  20 (7.54) 37 (7.50) 16 (8.04) 25 (9.92) 
New England 21 (4.76) 76 (6.49)  3 (1.13) 23 (4.66) 7 (3.52) 8 (3.17) 
Pacific 51 (11.56)  171 (14.60)  36 (13.58) 55 (11.16) 27 (13.57) 31 (12.30) 
South Atlantic 88 (19.95) 224 (19.13)  45 (16.98) 113 (22.92) 37 (18.59) 57 (22.62) 
West North Central 32 (7.26) 90 (7.69)  30 (11.32) 37 (7.50) 19 (9.55) 21 (8.33) 
West South Central 46 (10.43) 111 (9.49)  31 (11.7) 48 (9.74) 13 (6.53) 27 (10.71) 
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 Table  2-1 Distribution of socio-demographic, health related, behavioral, and knowledge related characteristics  
Independent Variables 
Women’s intentions and attitudes toward 
mammography 
Thinking about 
mammogram in non-
adherent women 
Age < 65 (N=1612)  Age ≥ 65 (N=758)   ∗ = 0 
(N=441) 
 =1 
(N=1171) 
T∗∗ = 0 
(N=265) 
T = 1 
(N=493) 
?ϯ = 0 
(N=199) 
? = 1 
(N=252) 
 Missing 0 (0) 0 (0)  0 (0) 0 (0) 0 (0) 0 (0) 
Health-related characteristics 
Body mass index 
(BMI) 
Underweight 8 (1.81) 18 (1.54)  10 (3.77) 8 (1.63) 9 (4.52) 5 (1.98) 
Normal 148 (33.56) 475 (40.56)  96 (36.23) 184 (37.32) 86 (43.22) 84 (33.33) 
Overweight 112 (25.40) 321 (27.41)  68 (25.66) 190 (38.54) 51 (25.63) 70 (27.78) 
Obese 114 (25.85) 306 (26.13)  50 (18.87) 97 (1.97) 36 (18.09) 78 (30.95) 
 Missing 59 (13.37) 51 (4.35)  41 (15.47) 14 (2.84) 17 (8.54) 15 (5.95) 
 
Less than twice a year 85 (19.27) 197 (16.82)  29 (10.94) 60 (12.17) 86 (43.22) 107 (42.46) 
2 to 4 times a year 135 (30.61) 519 (44.32)  120 (45.28) 214 (43.41) 59 (29.65) 88 (34.92) 
5 or more a year 93 (21.09) 405 (34.59)  74 (27.92) 201 (40.77) 49 (24.62) 56 (22.22) 
 Missing 128 (29.02) 50 (4.23)  42 (15.85) 18 (3.65) 5 (2.51) 1 (0.40) 
Family history of 
cancer 
No 145 (32.88) 324 (27.67)  97 (36.60) 148 (30.02) 75 (37.69) 77 (30.56) 
Yes 294 (66.67) 844 (72.07)  166 (62.64) 342 (69.37) 123 (61.81) 175 (69.44) 
 Missing 2 (0.45) 3 (0.26)  2 (0.75) 3 (0.61) 1 (0.50) 0 (0) 
Psychological distress 
No 355 (80.50) 1084 (92.57)  221 (83.40) 471 (95.54) 179 (89.95) 226 (89.68) 
Yes 46 (10.43) 69 (5.89)  11 (4.15) 11 (2.23) 10 (5.02) 24 (9.52) 
Missing 40 (9.07) 15 (1.54)  33 (12.45) 11 (2.23) 10 (5.02) 2 (0.79) 
Have been advised to 
have a mammography 
No 133 (30.16) 111 (9.48)  120 (45.28) 49 (9.94) 111 (55.78) 96 (38.09) 
Yes 155 (35.15) 1012 (86.42)  92 (34.72) 429 (87.02) 33 (16.58) 94 (37.30) 
 Missing 153 (34.69) 48 (4.09)  53 (20) 15 (3.04) 55 (27.64) 62 (24.60) 
Having had Pap smear No 8 (1.81) 6 (0.51)  26 (9.81) 10 (2.03) 23 (11.56) 8 (3.17) Yes 383 (86.84) 1127 (96.24)  209 (78.87) 472 (95.74) 165 (82.91) 234 (92.86) 
 Missing 50 (11.34) 38 (3.24)  30 (11.32) 11 (2.23) 11 (5.53) 10 (3.97) 
Behavioral characteristics 
Trust cancer info from 
doctors 
Not at all 10 (2.27) 4 (0.34)  9 (3.34) 4 (0.81) 9 (4.52) 4 (1.59) 
A little  35 (7.94) 46 (3.93)  15 (5.66) 20 (4.06) 19 (9.55) 14 (5.56) 
Some 162 (36.73) 392 (33.48)  89 (33.58) 131 (26.57) 73 (36.68) 88 (34.92) 
A lot 224 (50.79) 716 (61.14)  148 (55.85) 330 (66.94) 95 (47.74) 143 (56.75) 
 Missing 20 (4.53) 13 (1.11)  4 (1.51) 8 (1.62) 3 (1.51) 3 (1.19) 
Looking for cancer 
information 
No 217 (49.21) 443 (37.83)  182 (68.68) 280 (56.79) 144 (72.36) 123 (48.81) 
Yes 224 (50.79) 726 (62.00)  82 (30.94)  210 (42.60) 54 (27.14) 129 (51.19) 
 Missing 0 (0) 2 (0.17)  1 (0.38) 3 (0.61) 1 (0.50) 0 (0) 
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 Table  2-1 Distribution of socio-demographic, health related, behavioral, and knowledge related characteristics  
Independent Variables 
Women’s intentions and attitudes toward 
mammography 
Thinking about 
mammogram in non-
adherent women 
Age < 65 (N=1612)  Age ≥ 65 (N=758)   ∗ = 0 
(N=441) 
 =1 
(N=1171) 
T∗∗ = 0 
(N=265) 
T = 1 
(N=493) 
?ϯ = 0 
(N=199) 
? = 1 
(N=252) 
Perception of chance 
of getting breast 
cancer 
Low 209 (47.39) 541 (46.20)  157 (59.24) 265 (53.75) 134 (67.34) 130 (51.59) 
Moderate 129 (29.25) 414 (35.35)  58 (21.89) 156 (31.64) 43 (21.61) 82 (32.54) 
High  49 (11.11) 184 (15.71)  11 (4.15) 44 (8.92) 6 (3.01) 31 (12.30) 
 Missing 54 (12.24) 32 (2.73)  39 (14.72) 28 (5.68) 16 (8.04) 9 (3.57) 
Fruit and vegetable 
consumption 
Per day  193 (43.76) 615 (52.52)  137 (51.70) 306 (62.07) 32 (16.08) 43 (17.06) 
Per week 113 (25.62) 333 (28.44)  59 (22.26) 110 (22.31) 52 (26.13) 74 (29.36) 
Per Month 76 (17.23) 199 (16.92)  37 (13.96) 70 (14.20) 99 (49.75) 122 (48.41) 
 Missing 59 (13.38) 24 (2.05)  32 (12.07) 7 (1.42) 16 (8.04) 13 (5.16) 
Lifetime number of 
smoked cigarettes 
<100 187 (42.4) 642 (54.82)  152 (57.36) 283 (57.40) 112 (56.28) 120  (47.62) ≥ 100 221 (50.11) 526 (44.92)  87 (32.83) 207 (41.99) 86 (43.22) 131 (51.98) 
 Missing 33 (7.48) 3 (0.26)  29 (9.81) 3 (0.61) 1 (0.50) 1 (0.40) 
Exercise in the past 
month 
No 137 (31.06) 840 (71.73)  133 (50.19) 334 (67.75) 77 (38.69) 90 (35.71) 
Yes 267 (60.54) 321 (27.41)  105 (39.62) 154 (31.24) 116 (58.69) 159 (63.09) 
 Missing 37 (8.39) 10 (0.85)  27 (10.19) 5 (1.01) 6 (3.01) 3 (1.19) 
Knowledge of Breast Cancer/Mammography 
Age at which women 
should start getting 
mammography 
40-50 227 (51.47) 755 (64.47)  87 (32.83) 280 (56.79) 89 (44.72) 132 (52.38) 
Others 140 (31.75) 371 (31.68)  83 (31.32) 144 (29.21) 58 (29.15) 95 (37.70) 
 Missing 74 (16.78) 45 (3.84)  95 (35.84) 69 (13.99) 52 (26.13) 25 (9.92) 
Frequency of getting 
mammograms  
Every 1 to 2 years 257 (58.28) 909 (77.63)  136 (51.32) 384 (77.89) 106 (53.27) 159 (63.09) 
Others 118 (26.76) 249 (21.26)  68 (25.66) 97 (19.67) 57 (28.64) 79 (31.35) 
 Missing 66 (14.97) 13 (1.11)  61 (23.02) 12 (2.43) 36 (18.09) 14 (5.55) 
15
 
 16 
 
For the health-related characteristics, as the number of visits to a health care provider increases, 
women are more likely to adhere to screening mammography (OR=2.358 for women with more 
than 5 visits to doctor per year versus women with less than two visits per year). Being advised 
to have mammogram is the strongest factor in this category OR= 5.298 and 10.711 for women 
younger than 65 and women 65 and older, respectively compared to women who are not advised. 
Women who have had a prior Pap smear are more adherent than those who have not (OR=3.203 
and OR=3.809 for women younger than 65 and women 65 and older, respectively).  
For the behavioral characteristics, women who trust the cancer information from their doctor “a 
little”, “some” and “a lot” are 6.727, 13.194, and 14.824 times more likely to adhere compared to 
women who do not trust their doctor at all. Women who have an increased risk perception of 
breast cancer are more adherent. For women younger than 65, the corresponding ORs for women 
with “moderate” and “high” risk perception are 1.519 and 1.541, respectively. The corresponding 
values for women older than 65 are 1.645 and 3.036, respectively. Women younger than 65, who 
have smoked at least 100 cigarettes in their lifetimes are less likely to be adherent (OR=0.687).  
For the knowledge related class of factors, women whose answer to the appropriate interval 
between two subsequent mammograms is other than every one or two years are less likely to 
adhere. The corresponding odds ratios are 0.812 and 0.636 for women younger than 65 and 
women 65 and older, respectively.  
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Table  2-2 Results for design-based multiple logistic regression on mammography adherence 
comparing women younger than 65 and women aged 65 and older 
Independent Variables 
Age < 65   Age ≥ 65  
Odds  
ratio  P-value 
 Odds  ratio  P-value 
 Socio-demographic characteristics 
Race 
Black -  - 
White 0.874 0.606  1.329 0.536 
Other 0.548 0.077  0.425 0.148 
Marital status Married -  - Single/Divorced/Separated 0.685 0.025  0.499 0.012 
Education 
 
Some high school or less -  - 
High school Graduate 1.750 0.089  1.460 0.310 
Some college/ College 
graduate 
1.457 0.231  1.507 0.320 
Income 
≤ $25,000 -  - 
>$25,000 and ≤$75,000 1.324 0.186  1.341 0.044 
>$75,000 2.526 0.004  1.992 0.609 
Insurance No -  - Yes 2.959 <0.0001  2.771 0.130 
 Health-related characteristics 
Number of visits to 
health provider a year 
Less than twice a year -  - 
2 to 4 times a year 1.618 0.019  1.016 0.969 
5 or more a year 2.358 0.001  1.610 0.313 
Being advised to have 
a mammography 
No -  - 
Yes 5.298 <0.0001  10.711 <0.0001 
Having had Pap 
smear 
No -  - 
Yes 3.203 0.0004  3.809 0.001 
 Behavioral characteristics 
Trust cancer info 
from doctors 
Not at all -  
NA A little  6.727 0.052  Some 13.194 0.007  
A lot 14.824 0.004  
Looking for cancer 
information 
No -  - 
Yes 1.134 0.457  0.883 0.484 
Perception of chance 
of getting breast 
cancer 
Low -  - 
Moderate 1.519 0.011  1.645 0.054 
High 1.541 0.079  3.036 0.043 
Lifetime number of 
smoked cigarettes 
<100 -  NA ≥ 100 0.687 0.047  
Exercise in the past 
month 
Yes NA  1.134 0.623 
No  - 
 Knowledge of Breast Cancer/Mammography 
Age at which women 
should start getting 
mammography 
40-50 -  - 
Others 0.921 0.605  0.692 0.101 
Frequency of getting 
mammograms  
Every 1 to 2 years -  - 
Others 0.812 0.043  0.636 0.048 
“-“ represents the reference group. 
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2.3.2 Thinking about Getting a Mammogram in Non-Adherent Women 
In the bivariate analysis, age, marital status, income, and insurance are among the variables, 
which proved to be significant in the socio-demographic class of factors. In the health related 
class of factors, being advised to have a mammography, having had Pap smear are statistically 
significant in bivariate analyses. Looking for cancer information, risk perception of breast cancer, 
lifetime number of smoked cigarettes, and exercise in the past month are significant factors in the 
bivariate analyses in the behavioral characteristics class.  
However, in the multiple logistic regression analyses (Table 2-3), the only significant factor is 
age. As women’s age increased, they reported thinking about getting mammograms less often. 
Women ages 60 to 69 years, and older than 70 years are 0.377 and 0.112 times less likely to 
think about getting a mammogram compared to women aged 42 to 49 years.  
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Table  2-3 Results for design-based multiple logistic regression on attitudes toward 
mammography in non-adherent women 
Independent Variables 
Non-Adherent Women (N=510) 
Odds  ratio (OR) P-value 
Socio-demographic characteristics 
Age 
42-49 - 
55-59 0.784 0.572 
60-69 0.377 0.015 
70+ 0.112 <0.0001 
Marital status Married - Single/Divorced/Separated 0.965 0.917 
Income 
≤ $25,000 - 
>$25,000 and ≤$75,000 1.579 0.193 
>$75,000 1.738 0.363 
Insurance No - 
Yes 1.277 0.496 
Health-related characteristics 
Being advised to have 
a mammography 
No - 
Yes 1.789 0.083 
Having had Pap smear No - 
Yes 1.156 0.727 
Behavioral characteristics 
Looking for cancer 
information 
No - 
Yes 1.676 0.081 
Perception of chance 
of getting breast 
cancer 
Low - 
Moderate 1.412 0.207 
High 2.049 0.337 
Lifetime number of 
smoked cigarettes 
<100 - ≥ 100 0.817 0.541   
Exercise in the past 
month 
No - 
Yes 1.061 0.848 
Knowledge of Breast Cancer/Mammography  
Age at which women 
should start getting 
mammography 
40-50 - 
Others 1.102 0.737 
Frequency of getting 
mammograms 
Every 1 to 2 years - 
Others 0.967 0.925 
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2.3.3 Evaluation of Regression Models  
Table 2-4 and 2-5 present the classification tables for the first response variable and the second 
response variable, respectively. Sensitivity, specificity and accuracy of the proposed logistic 
regression models are presented in the tables. Note that the numbers presented in the tables are 
weighted according to the replication jackknife weights in the data to be representative of the 
national population. For example, the number 4,727,850 in Table 2-4 is the number of non-
adherent women younger than 65 who are correctly classified as non-adherent by the design 
based logistic regression. 
 
Table  2-4 Classification table of logistic regression model on mammography adherence*  
  Actual Data  
  
Non-Adherent 
(T=0) Adherent (T = 1  
Logistic 
Regression 
Model Result 
Younge
r than 
65 
W <	0.5 4,727,850 7,816,121 
Accuracy=77.7 W ≥	0.5 2,234,154 30,291,566 
Measures Specificity=67.91 Sensitivity=79.49 
65 and 
older  
WT <	0.5 3,914,902 2,164,589 
Accuracy=80.50 WT ≥	0.5 1,086,976 9,505,231 
Measures Specificity=78.27 Sensitivity=81.45 
* W1 and W2 are the adherence likelihood calculated from the logistic regression models for women younger than 65 
and women 65 and older, respectively. 
 
Table  2-5 Classification table of logistic regression model on attitudes toward mammography in 
non-adherent women 
  Actual Data  
  
Do not think about 
getting a 
mammogram (?=0) 
Think about getting 
a mammogram 
(?=1)  
Logistic 
Regression 
Model Result 
?̂ < 0.5 3,427,551 2,071,371 
Accuracy=74.43 ?̂ ≥ 0.5 1,290,733 6,360,130 
Measure Specificity=72.64 Sensitivity=75.43 
*  ?W is the likelihood of being concerned about getting mammogram in non-adherent women calculated from the 
logistic regression model. 
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As the results show, for the adherence to mammography response variable the proposed design-
based logistic regression models correctly classify 77.7% of women younger than 65 and 80.5% 
of women 65 and older. For the thinking about getting a mammogram response variable 73.43% 
of women are correctly classified.  
2.4 Conclusion 
In this study, we evaluated the association between women’s adherence to mammography 
screening and four classes of factors including various socio-demographic, health-related, 
behavioral characteristics and knowledge of breast cancer/mammography factors using the 2003 
HINTS data.  
In the literature, definitions of adherence to mammography screening vary widely across studies. 
Zapka et al. [14] and Wu et al. [15] defined adherence based on the ACS guideline, “had a 
mammogram in the last year”. Maxwell et al. [16], Murabito et al. [17], Tejeda et al. [18], 
Schonberg et al., [19] and Vyas, et al. [20], considered “had a mammogram in the past two years” 
as a measure of adherence, which is consistent with the USPSTF guideline. Wu et al. [15], 
Maxwell et al. [16], Tejeda et al. [18] and Meissner et al. [21] considered “ever had a 
mammogram” to measure women’s decisions in mammography participation. However, this 
measure cannot be interpreted as the adherence to mammography guidelines since it does not 
incorporate a specific time interval.  Other time intervals are also considered in the literature. For 
example, Harrison et al. [22] defined “had any mammogram in the preceding 5-year period” as 
their response variable. Many studies defined adherence based on “ever had” or “the most recent” 
mammogram rather than considering whether the women returned for repeat mammography or 
not. To bridge this gap, Carney et al. [23] defined the response variable as “returning for a 
screening mammogram within 24 months of the initial exam” and identified factors that had 
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significant effect, such as health insurance coverage, first degree relatives with breast cancer, and 
knowledge about breast cancer. In other studies, Allen et al. [24. 25] explored the relationship 
between mammography use and social network characteristics while considering “receipt of at 
least two mammograms, the most recent of which was within the past 2 years with a maximum 
interval of 2 years between screenings” as the adherence measure. Rakowski et al. [26] 
considered “two exams on schedule, based on an every-other-year interval” in their study. A 
systematic literature review of the studies on the mammography use and the associated factors 
published from 1988 to 2004 was completed by Schueler et al. [27]. In summary, they found that 
the strongest predictors of mammography use were past screening behavior (clinical breast 
examination and Pap test), having access to a physician, and having a physician-recommend 
mammography. These results are in line with our findings as the design based logistic regression 
result show that “having been advised to get mammogram”, “have had Pap test” are the two most 
important factors. We also found that “perception of chance of getting breast cancer”, “income”, 
“insurance” and “knowledge about mammography” are significant factors. 
Most of these studies used data at the local, regional or state level, making national 
generalizations difficult. In addition, these studies did not consider if a woman underwent a 
mammogram because she intended to do so, or for a diagnostic purpose (e.g. after the woman 
had felt a lump in her breast), or because her doctor prescribed the mammogram. In addition, for 
the studies that used longitudinal data (sequential mammograms), it is difficult to keep track of 
women who died, moved, etc. This can potentially cause bias in the data analysis, and as a result, 
these measures may not truly represent women’s adherence to mammography guidelines.  
This study differs from prior studies [14-27] in that adherence is defined based on women’s 
intention and plans of obtaining mammograms rather than their mammography history behavior. 
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Results from our work will likely helps decision makers to differentiate between women who are 
concerned about mammography and have regular plans for getting mammograms from those 
who are not concerned. The results of this analysis can help policy makers identify non-adherent 
populations. We also examine the relationship between aforementioned four classes of factors 
with women’s attitudes toward getting mammograms for women with poor mammography 
history. By characterizing the factors associated with attitudes toward mammography in the non-
adherent population, policy makers can differentiate between the women who are concerned 
about receiving a mammogram but may have some barriers versus those who are not concerned 
at all.  
As for the limitations of our study, it is based on self-reported data and may yield biased results 
if a woman did not report the exact time of her last mammogram. We also used the 2003 HINTS 
data set since it is the only HINTS data that provides information on women’s intention toward 
mammography. 
Adherence to screening mammography is lower among minorities [28]. Based on the 2010 
National Health Interview Survey, 69.4% of American Indian/Alaska native women and 64.1% 
of Asian women had a mammogram between 2008 and 2010, while participation rates among 
white and black women were about 72.8% and 73.2%, respectively [29]. Our results also imply 
that the percent of women intending to have regular screening mammography is lower in races 
other than white and black. However, we do not have enough evidence to conclude that these 
differences are statistically significant. The results reveal that for both age groups, married 
women are more likely to comply with the mammography guidelines. For women younger than 
65, financial aspects such as insurance and income are also significant factors the policy makers 
should consider for improving adherence. 
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Physicians’ involvement in achieving mammography adherence is important. However, many 
physicians do not make referrals at the recommended intervals, even though they may endorse 
the guidelines [30]. Our results show that prior advice to have a mammogram by the woman’ 
physician is the most significant factor in health related class of factors. This suggests that to 
enhance women’s adherence, doctors should recommend that their patients have regular 
screening mammograms. Mammography referrals are more frequent for women who have access 
to the health care system (i.e. women with regular physician and health insurance), but less 
frequent among vulnerable women, (i.e., older women with lower educational attainment or 
lower annual family income [31]). It would be worth investigating the factors associated with 
low mammogram referral rates by physicians. Having history of Pap smear was found to be 
significant for both age groups. This is in line with a previous study by Augustson et al. [32], in 
which they characterize the association between clinical breast exam (CBE), Pap smear, fecal 
occult blood testing (FOBT) adherence, and mammography adherence. Therefore, low 
compliance with other cancer screenings can help identify women in need of additional 
interventions to improve mammography adherence. Although the number of visits to a health 
provider is significant for women younger than 65, this factor is not significant for older women. 
This is interesting as older women, regardless of being adherent or not, are expected to visit their 
doctors more frequently than younger women because of aging associated diseases.  
In the behavioral characteristics class, “lifetime number of smoked cigarettes” is a significant 
factor for younger women but not for older women. Trusting doctor’s information about cancer 
is proved to be significant for younger women, however, we do not have enough evidence to say 
that it is also significant for older women. Previous studies differ about whether fear motivated 
or inhibits precautionary behaviors. McCaul et al. tested different predictors in the context of fear 
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of breast cancer and breast cancer screening and showed that greater fear was related to higher 
levels of screening intentions and behaviors [33]. Our data analysis confirms this finding and 
shows that risk perception of breast cancer is a significant predictor on intention of getting 
regular mammograms for both age groups.  
For the last class of covariates, as expected, knowledge about frequency of getting mammograms 
is significant. Thus, increasing women’s knowledge about breast cancer and mammography 
recommendations is also likely to significantly influence women’s adherence. 
For the second response variable (thinking about getting a mammogram in non-adherent women), 
we found little difference between women who are and are not concerned about getting 
mammograms. For this response variable, younger women are more likely to think about 
obtaining a mammogram. Women who have been advised to get a mammogram before and those 
who are looking for cancer information may be more concerned about getting mammograms, 
although these findings are not statistically significant. 
This study enables decision makers to identify barriers women may face to obtain a screening 
mammogram and also allows for the identification of characteristics of non-adherent women 
who are not concerned about getting a mammogram. Our findings suggest the most significant 
factors influencing women’s compliance are being advised to have a mammogram and insurance. 
The former has been applied on a systematic level in some European countries (e.g. the UK, 
Sweden, Norway), which have organized population-based screening programs where women 
are invited through a personal letter for a free mammogram every two or three years [34]. A 
recent analysis of the European Network for Information on Cancer (EUNICE) data for years 
2005, 2006 and/or 2007 (10 national and 16 regional programs for women aged 50-69 in 18 
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European countries) reported that in 13 of the 26 programs the participation rate exceeded the 
European Union benchmark of 70%, and 9 programs achieved a participation level >75% [35]. 
According to the CDC, 66.6% and 67.1% of U.S. women 40 years and over received a 
mammogram in the past two years based on data from 2005 and 2008, respectively [8]. Although 
a direct comparison of screening mammography participation rates between European countries 
and the U.S. is difficult due to difference in recommendations (i.e. age at which to begin 
screening, interval between mammograms), our results support the benefit of future policies that 
systematically advise and provide resources to women to receive a mammogram, as is already 
done in other countries. Several studies also identified significant factors associated with 
attendance in population-based mammography programs in European countries (the UK, France 
and Sweden) [36-41]. Some of these factors such as income, visiting healthcare providers, 
having had Pap smear and perceived risk of breast cancer are also found significant in our 
analysis. As in most European countries mammography is free, none of these studies reported 
insurance as an influencing factor for getting a mammogram. However, as our results show, lack 
of insurance is still a barrier in the U.S., especially for women younger than 65. 
In summary, sending reminders and having insurance were shown to be the most influential 
factors in screening mammography. Other significant factors include marital status, number of 
visits to health provider a year, having had Pap smear, risk perception of breast cancer, and 
knowledge of breast cancer/mammography.  These findings can help in designing programs 
aimed at improving screening rates and provides policy makers with data to allow for 
interventions to remove these barriers and make the targeted population more concerned about 
getting breast cancer screenings.   
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 Evaluation of breast cancer mammography screening policies considering adherence 3
behavior 
3.1 Introduction 
Mammography screening recommendations have been the subject of significant debate in recent 
years.  As discussed in Chapter 2, there are varying screening guidelines from different 
organizations about when to start and end mammograms and how frequently a woman should 
undergo mammography screenings. For example, the American Cancer Society (ACS), the 
department of Health and Human Services (HHS), the American Medical Association (AMA), 
and the American College of Radiology (ACR) recommend screening mammography every year, 
beginning at age 40. In 2009, the U.S. Preventive Services Task Force (USPSTF) issued revised 
screening mammography guidelines, which resulted in a significant controversy. According to 
the USPSTF guidelines, screening mammograms should be done every two years between age 
50 and 75 for women at average risk of breast cancer [1].  
Although mammography is known to be one of the most effective methods of detecting breast 
cancer, there are many concerns on its adverse effects on women’s quality of life. Unreliability 
of mammography, i.e., false negative and false positive results and overdiagnosis are among the 
deficiencies of mammography [2]. A prospective cohort study of 7 mammography registries of 
the Breast Cancer Surveillance Consortium (BCSC) showed that the adjusted sensitivity 
increased with age from 68.6% in women ages 40 to 44 to 83.3% in women ages 80 to 89 
[3].  Similarly, the specificity rate increased from 88.2% for women aged 40 through 44 years to 
93.4% in women older than 75 [4]. Moreover, about one-third of all aggressive cancers are 
diagnosed in the interval between successive annual mammograms [5]. These cancers are known 
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as interval cancers and are defined as cancers detected within 12 months after a negative 
mammogram [6]. Some of the interval cancers are present at the time of mammography 
screening (false-negatives) while others grow rapidly in the interval between a mammogram and 
detection [7]. Generally, interval cancers grow rapidly and are frequently diagnosed at advanced 
stages [8]. In addition, studies have shown that receiving mammograms increases a woman’s 
chance of developing breast cancer due to exposure to radiation [2, 9-10]. Each radiation-
absorbed dose (rad) of exposure increases breast cancer risk by 1 percent [2]. Moreover, Bleyer 
et al. also found that up to a third of diagnosed breast cancers are overdiagnosed cases and do not 
need treatment [11]. 
Various studies have been conducted to evaluate and compare different screening policies or to 
identify optimal policies. Kirch et al. [12] developed an inspection strategy for the detection of 
an age-dependent disease with the objective of minimizing detection delay. To illustrate their 
methodology, they developed optimal schedules for breast cancer examinations. Shwartz [13] 
developed a mathematical model to evaluate life expectancy gain associated with different 
screening policies under different assumptions about the rate of disease progression, the 
characteristics of the screening technique, and the frequency of screenings. Parmigiani [14] 
presented a continuous time non-Markovian stochastic process model of disease progression to 
analyze which age groups and what part of the population should undergo breast cancer 
screening, while minimizing the total expected loss or risk including financial costs, side effects, 
wasted time, stress due to false-negative test results, etc. Zelen [15] formulated a screening 
scheduling problem to maximize a weighted utility function in a continuous time setting. In 
Zelen’s model all the parameters were assumed to be stationary except for the incidence rate. 
Baker [16] used a mathematical parametric model to assess different screening policies in terms 
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of minimizing the cost of cancer plus the cost of carrying out any screening. Baker’s model was 
developed based on a small data set used to estimate the model parameters, and compares a small 
set of cost optimal policies under different sets of constraints. Hanin et al. [17] developed a 
model to study screening strategies based on tumor size at detection. In their model they 
combined several processes such as tumor latency, tumor growth and tumor detection to estimate 
the tumor size at detection. As a measure of the screening efficiency, they proposed the 
difference between the expected tumor sizes at detection with and without screening, when both 
spontaneous and screening-based detections are in place. They concluded that in the case of 
exponential tumor growth, the optimal screening schedules with a fixed number of exams are 
uniform or very close to uniform (same interval between subsequent screening tests). Maillart et 
al. [18] formulated a partially observable Markov chain model to evaluate a wide range of 
dynamic mammography screening policies as well as current practices. They compared different 
policies in terms of the resulting lifetime breast cancer mortality risk and the expected number of 
mammograms women should undergo for each policy and generated a frontier of efficient 
policies. In their formulation, they considered age-based dynamics of breast cancer (i.e., 
increasing incidence, decreasing aggression). They also incorporated the imperfect nature of the 
screening outcomes and dynamics of test result accuracy (increasing sensitivity and specificity 
rates with age). Ayer et al. [19] developed a finite-horizon partially observable Markov decision 
process (POMDP) model to determine the optimal personalized mammography screening 
strategy based on personal risk characteristics of women such as their prior screening history. 
Ahern et al. [20] developed a mathematical model to optimize cancer screening schedules, taking 
into account the trade-off between the benefits and costs of screenings in their proposed utility 
function. They considered two different optimization frameworks: optimize the number of 
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screening examinations with equal screening intervals between exams but without a pre-fixed 
total cost; and optimize the ages at which screening should be given for a fixed total cost and 
prove that the optimal solution exists under each of the two frameworks.  In another study, Hanin 
et al. [21] developed a model to construct optimal schedules of cancer screening that maximize 
the probability that by the time of primary tumor detection, it has not yet metastasized. They 
applied their model to mammographic screening for breast cancer. Their model includes all main 
stages of cancer progression: cancer latency, primary tumor growth, its detection and metastatic 
spread.  
However, none of the above mentioned studies have taken patient behavior into consideration. 
They all assume that patients adhere to the guidelines perfectly and undergo the prescribed 
screening mammograms. This is also true for the current screening recommendations which are 
based on the assumption of 100% adherence to the guidelines. However, as discussed in Chapter 
2, not all women have the same attitudes toward breast cancer screening. There are a limited 
number of studies taking individual adherence behavior into consideration. Brailsford et al. [22] 
used a three-phase discrete event simulation to model breast cancer and screening policies 
incorporating women’s behavioral factors in their model. They assigned behavioral attributes to 
each simulated woman to control her compliance with the prescribed mammograms in their 
model. They compared a limited number of screening policies, including the current UK policy, 
in terms of the number of screen detected cancers, and life yeas saved. In another study, Ayer et 
al. [23] analyzed the role of behavioral heterogeneity in women's adherence on optimal 
mammography screening recommendations.  
In this research, incorporating women’s adherence behavior to mammography recommendations, 
a mathematical framework is proposed to evaluate and compare various screening policies in 
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terms of QALYs and the lifetime mortality risk of breast cancer. Our study is different from the 
two studies discussed above in the approach of incorporating patient adherence to the screening 
tests. In contrast to earlier studies, we allow uncertainty in a patient’s adherence probabilities in 
the model. Adherence is also a function of the length of the interval between two subsequent 
screenings. Moreover, assuming a patient’s adherence behavior is related to and can be estimated 
from her perception/planning toward mammography, not only can we evaluate and compare 
screening policies for a specific patient knowing her personal characteristics, but we can identify 
efficient policies for the general population as well. In addition, we incorporate in our model the 
possibility of interval cancer detection, and the increased risk of developing breast cancer due to 
exposure to X-ray radiation during a mammography test.  
The remainder of this chapter is organized as follows. In Section 3.2, the proposed model is 
presented. In Section 3.3, model inputs and parameters estimation, and computational results are 
presented. Finally, Section 3.4 summarizes the findings and discusses future work.  
3.2 Model Formulation 
A randomized discrete-time finite-horizon partially observable Markov chain model is developed 
to evaluate various mammography screening policies in terms of the expected QALYs and 
lifetime breast cancer mortality risk. This problem is formulated as a partially observable 
Markov chain because the women’s true health states are not outwardly observable due to the 
imperfect nature of mammography screening tests. 
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Figure  3-1 One period sample path of the breast cancer detection process 
The model takes into account two methods of detection: screening mammography and self-
detection (SD), i.e., breast self-examination. Interval cancer detection is considered separately 
from self-detection, depending on the time interval between the detection and the last 
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mammogram. The detailed mammography screening process is presented in Figure 1 and is 
described as follows.  
At epoch t if a mammogram is recommended, a woman may undergo the recommended 
mammogram with probability Z[ or skip it with probability 1 − Z[. If she undergoes the 
prescribed mammogram, she may receive a positive or negative result. After a positive result, 
since mammography is not perfect and has a relatively low sensitivity (the probability of 
receiving true positive result), a breast biopsy test is usually conducted to check the suspicious 
area found on a mammogram and see whether the result is true positive or not. Biopsy is 
assumed to be perfect since it has a relatively high sensitivity and specificity (probability of 
receiving true negative) rates [24]. If the biopsy result is negative suggesting a false positive 
mammogram, the patient proceeds to the next epoch. However, if the biopsy confirms the 
mammographic findings, cancer is detected and the patient leaves the model. We do not model 
the treatment explicitly. Instead, we assume that when the patient is diagnosed with breast cancer, 
regardless of the method of detection, she receives a terminal (lump sum) reward and leaves the 
model. After a negative result, the woman proceeds to the next epoch. However, it is possible 
that after a negative result the cancer becomes symptomatic and be detected (interval cancer 
detection in this case). 
If the woman skips the recommended mammogram or the recommended action at time t is to 
wait, she may or may not develop some symptoms suggesting there is cancer present. If she 
develops symptoms, depending on the action in the previous epoch we have either a self-
detection (if the previous action is a wait), or an interval cancer (if the previous action is a 
mammogram). Note that the interval between two decision epochs in the process is six month. 
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Therefore, if the action in a previous epoch was a mammogram and symptoms occur after the 
current epoch, we have an interval cancer and not a self-detection. We assume that when the 
woman feels a lump in her breast (symptom) she would go for a mammogram, and if the result 
of the mammogram is positive, she would have a biopsy test to confirm that the cancer is present. 
If both the mammography and biopsy tests are positive, similar to the previous case the patient 
leaves the model. However, if the follow-up tests (i.e., mammogram or biopsy) are negative, the 
patient proceeds to the next epoch. 
For consistency, we refer to the woman as the “patient,” irrespective of her health condition. 
Below is the list of notation used in the problem formulation.  
t Decision epochs, [ = 0,… , \. We consider the earliest and latest age a policy may 
recommend a patient undergo a mammogram to be 40 and 100, respectively. The 
start age of 40 is considered in order to be consistent with the current 
mammography screening policies (e.g. ACS). In addition, we assume the process 
ends at age 100 because of the negligible probability of surviving after this age 
according to the U.S. life tables [25]. Mammography decisions are made every six 
months. Patients enter the process at age 40 ([ = 0 and, if cancer is not detected, 
stay in the process up to age 100 ([ = \ = 120), regardless of the policy under 
study. 
]! Underlying health state a patient occupies at epoch t and	]! ∈ S = {0, 1, 2, 3, 4}. 
The five states considered in the model are cancer free (state 0), early breast cancer 
(state 1), advanced breast cancer (state 2), death from breast cancer (state 3), and 
death from other causes (state 4). We define cancer states similarly to Maillart et al. 
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[18]. States 0 through 2 are partially observable due to the imperfect nature of 
mammography tests. However, states 3 and 4 are fully observable. 
R! Action prescribed at time t, and	R! ∈ c = {W,M}. W and M represent “Wait” and 
“Mammogram”, respectively. 
1! Belief state distribution, where 1! = [1!0, 1!1, 1!2] and represents the 
occupancy distribution of partially observable states at which the patient is believed 
to be, i.e., 1!] represents the probability that a patient is believed to be in state s. 
P!]́|], R Underlying transition probability, i.e., the probability of being in state	]́ at time	[ +1, when the patient is in state s and takes action a at time t. Note that the transition 
probability is a function of action R since undergoing a mammogram increases the 
patient’s chance of developing radiation-induced breast cancer.  
=jk  Observation when a patient takes action R!. If	R! = M, the observation space is 
lm = {M+,M−}, where M+ 	and, M − represent a positive mammogram, and a 
negative mammogram, respectively. In the case of receiving a negative 
mammogram (M−, the patient may show symptoms within one year, which results 
in interval cancer detection. In this case the observation space is	lno = {IC+, IC−}, 
where IC + and IC −	represent interval cancer and no interval cancer, respectively. 
If	R! = W and the patient did not have a mammogram test within the past year, 
then lq = {SD+, SD−}, where SD + and SD − represent self-detection and no 
self-detection, respectively. 
s!o|s, R Observation probabilities, i.e., the probability of observing o at time t when the 
patient is in state s and action a is taken at time t. Note that for the case that 
observation is IC + or	IC −, for simplicity, we use the notation s!o|s since 
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interval cancers can happen both after a wait and a mammogram action. However, 
in “wait” cases we should have had a mammogram in the previous epoch (at time 
[ − 1 or six month prior to time [). 
>!]|R, = Immediate reward that a woman receives when she is at state s, takes action a and 
receives observation o at time t. 
I,!]							 The total expected reward a patient receives when she is in one of the cancer states 
(s= 1 or 2) and her cancer is detected through screening mammography. 
IT,!] The total expected reward when a patient is in cancer state s in the case of interval 
cancer or when the cancer is diagnosed via self-detection. Different total expected 
reward values are considered for screen-detected and symptomatic cancers since 
previous studies have shown a systematic survival benefit for screen-detected 
cancers comparing to symptomatic cancers [26]. However, the expected reward for 
interval cancers and self-detected cancers is assumed to be the same as it has been 
shown that there is no statistical difference in survival between interval cancers and 
clinical cancers [27]. 
w,!]								 Probability of eventually dying from breast cancer when the cancer is diagnosed 
through screening mammography and the patient is in state s (=1 or 2) at time t. 
wT,!] Probability of eventually dying from breast cancer in the case of interval cancer or 
when the cancer is diagnosed through self-detection. 
tγ  Probability of dying from causes other than breast cancer. Note that tγ is 
independent of the state the patient is in and (4 | , )t tP s aγ = . 
x[ Indicator function representing whether the previous action at epoch [ − 1 was a 
mammogram (x[ = 1) or not (x[ = 0). 
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d Mammography screening policy or a sequence of prescribed actions 
d=(y, , … , z where ! represents the action at time t under policy d. 
F!m Disutility of mammography at time t. 
F!{ Disutility of biopsy at time t. Z[ Probability that a woman undergoes the prescribed mammogram at epoch t. q(t) 
varies in the interval of [Z[		ZT[], where Z	[ and		ZT[	 are bounds of the 
confidence interval of the adherence probabilities and can be estimated based on 
the woman’s various characteristics. Estimation for Z	[	and	ZT[	is discussed in 
Section 3.1.  
The state transition diagram of the underlying Markov chain representing the disease natural 
history is presented in Figure 3-2.  Note that cancer death only occurs when the cancer 
progresses to an advanced stage [18]. 
 
 
 
 
 
 
Figure  3-2 Transitions between different health states 
 
The policies are evaluated and compared in terms of two outcome measures: total expected 
quality adjusted life years (QALYs), and lifetime mortality risk of breast cancer. 
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The value functions of policy d in our model follows a randomized Markov model in which the 
actions are chosen under uncertainty, i.e., at age t the woman may take action M (mammogram) 
with probability ( )q t  or choose to skip a mammogram (W) with probability1 ( )q t− . Given that 
1( )q t
 
and 2 ( )q t
 
are the lower and upper confidence bounds for ( )q t , the value function of 
policy d at time t is defined as below: 
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where V
t
a (pi )  is the value function at time t when the action a is taken and the occupancy 
distribution is	1.  Note that although 1 is a function of time as introduced in the notation section, 
we drop this time index in all equations for the clarity of the notation.  Equation 3-1 calculates 
the average value of function M W( ) ( ) (1 ( )) ( )t tq t V q t Vpi pi⋅ + − ⋅
 
over the interval 1 2[ ( ), ( )]q t q t . 
3.2.1 Total Expected Quality Adjusted Life Years (QALYs)  
Suppose ( )atϕ pi  represents the value function (Vta (pi )  in Equation 3-1) for our first outcome 
measure: the total expected quality adjusted life years (QALYs) the patient can attain when the 
current belief state distribution is	1 and action a is taken. If at time t the screening policy 
recommends a mammogram, then 
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where ~1, R, = is the updated occupancy distribution at time 1t +  when the current occupancy 
distribution (at time t) is 1 and action a is chosen and the result is observation o. ~1, R, =	is 
calculated using Equations 3-3a and 3-3b. 
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and,  
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Note that ( , , ) ( )a o spiξ  is the updated occupancy upon observing o at the current epoch and 
( , , ) ( ')a o spiϑ
 is the updated occupancy at the beginning of the next epoch. Time indices are dropped 
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for clarity.  The first line in Equation 3-3a represents the case when the patient undergoes a 
prescribed mammogram, receives a negative result and does not develop any symptoms within 
six months of the mammogram test. The second and third lines both represent the case when the 
recommended action is to wait in the current epoch. However, the second line is when the action 
at epoch t − 1 is a wait and the third line is when the recommended action at	t − 1 is a 
mammogram. These two cases need to be considered separately since the third case represents an 
interval cancer rather than self-detection because of the negative results in the previous 
mammogram at epoch t − 1	(within 12 month of a negative mammogram). The fourth line 
represents a false positive result. In such cases the follow-up tests reveal that the patient is 
healthy. In the case when the result is true positive (M+, SD+ and IC+ and	s = 1	or	2), the 
woman receives a lump sum reward and leaves the model. Therefore, no occupancy distribution 
update is needed. 
The logic of Equation 3-2 is as follows. When a patient undergoes a mammogram, she either 
receives a positive or a negative result. If the patient is in the cancer free state and she receives a 
negative result, an immediate reward is calculated and the patient will transit to time 1t + . If the 
patient is in cancer states but she receives a negative result, then she may develop some 
symptoms with probability (IC | )tQ s+
 
before the next epoch, which results in cancer detection. 
In this case, interval cancer is identified and the patient receives the lump sum reward and leaves 
the model. We assume that interval cancer can only occur in cancer states since even the fastest 
growing cancers cannot grow from a single cell to a symptomatic size within six months [28], 
which is the interval between two subsequent epochs in our model. If the patient does not 
develop any symptoms, she stays in the model and transits to time 1t + . If the woman is in the 
cancer free state and she receives a positive result, her true health state will be determined via a 
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follow-up biopsy and she remains in the model. However, if she is in any of the two cancer states 
and receives a positive result, she will receive a lump sum reward and the process is terminated.   
If the screening policy does not recommend a mammogram at time t, then the expected QALYs 
is calculated as 
4
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The logic of Equation 3-4 is as follows. When the action at time t is to wait (R! = W), as 
discussed above, two separate cases need to be considered: 1) the prescribed action at time [ − 1 
is to wait, and 2) the prescribed action at time [ − 1 is a mammogram. In Case (1), if the woman 
waits or does not get a mammogram at time t, there are two possible outcomes: whether 
symptoms are developed or not during the time interval between epoch t and
 t +1. In the case 
when no symptom develops, the patient receives an immediate reward (s, W,SD )tr − , remains in 
the model and her belief state distribution is updated using Equation 3-3a and 3-3b. However, if 
some symptoms are developed (with probability (SD+ | , W)tQ s ) and the patient is in the cancer 
free state, a follow-up test reveals her true health state, then her occupancy distribution is 
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updated and she remains in the model. If she is in a cancer state s (s=1, 2) and some symptoms 
are shown, the follow-up tests will detect the presence of breast cancer. In this case, the patient 
receives a lump sum reward R2,t (s)
 
and leaves the model. In Case (2), given that the patient had 
a negative mammogram at epoch	[ − 1, she may develop some symptoms (with probability 
Q
t
(IC+ | s)) that results in interval cancer detection in which case she receives a lump sum reward 
R2,t (s) and leaves the model. It is also possible that no symptom occurs, which means the patient 
receives an immediate reward ( , W, IC )r s
t
− , her belief state gets updated and she proceeds to the 
next epoch.  
Assuming ( , , )tr s W SD−
 
is determined, the immediate rewards in Equation 3-2 and 3-4 are 
calculated using the following relationship: 
M
M B
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3.2.2 Lifetime Breast Cancer Mortality Risk 
Suppose ( )atω pi
 
represents the value function (V
t
a (pi )) for the second outcome measure: the 
probability that the patient eventually dies from breast cancer when the current belief state is pi , 
and action a is taken at time t. If the screening policy recommends a mammogram at time t, then 
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If the patient does not get the prescribed mammogram at time t or the policy recommends the 
patient to wait, then her lifetime breast cancer mortality risk is 
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where ( , , )a oϑ pi
 
is the updated occupancy distribution as presented in Equations 3-3a and 3-3b. 
The logic behind the Equations 3-6 and 3-7 is as follows. If a patient undergoes the mammogram 
(Equation 3-6), she either receives a negative result or a positive one. If the mammography result 
is negative (with probability (M | , M)tQ s− ) and the woman is in the cancer free state (s=0), she 
may survive to time 1t +  with probability1 tγ− , and her risk of eventually dying from breast 
cancer is calculated by 11 ( ( , M, M ))tdtω ϑ pi++ − . If she is in the early stage cancer state (s=1) or 
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advanced cancer state (s=2), after receiving a negative result (false negative) she may develop 
some symptoms with probability (IC | )tQ s+ , which results in her cancer detection by follow-up 
tests (mammogram and biopsy if needed). In this case, her lifetime breast cancer mortality risk 
would be ρ2,t (s)  and she leaves the model. However, if she is in state	] = 1 (or	] = 2), and she 
does not develop any symptoms after a false negative result (with probability (IC | )tQ s− ), she 
survives to time 1t +
 
with probability 1−γ
t
 (or 1 (3 | 2, M, M )t tP γ− − − )
 
and her lifetime breast 
cancer mortality risk at time 1t +  is calculated by 11 ( ( , M, M &IC ))tdtω ϑ pi++ − − . Note that if the 
patient is in the advanced cancer state (] = 2, she may die from breast cancer in the current 
period with probability (3 | 2, M, M )tP − . If the mammography result is positive and the woman is 
in the cancer free state, her true health state will be determined via a follow-up biopsy and she 
survives to time 1t +  with probability 1 tγ−  and her value function is determined through
1
1 ( ( , M, M ))tdtω ϑ pi++ + . However, if she is in one of the cancer states, her probability of eventually 
dying from breast cancer would be ρ1,t (s) . 
In Equation 3-7, similar to Equation 3-4, two cases need to be distinguished, based on the action 
at time [ − 1, to account for the possibility of interval cancer. If the action at epoch [ − 1	is to 
wait then two outcomes in the current period are possible: developing symptoms ( (SD | ,W)Q st + ) 
and no symptoms ( (SD | ,W)Q st − ). If the patient does not develop any symptom when she is in 
the cancer free or early cancer state, she may survive to the next time period with probability 
1 tγ− . Then her lifetime breast cancer mortality risk is calculated using the recursive function at 
time [ + 1. However, if she is in the advanced cancer state, she will either die from breast cancer 
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before the next period with probability (3 | 2, W,SD )tP −  or survive to the next period with 
probability1 (3 | 2, W,SD )t tP γ− − − and her probability of eventually dying from breast cancer is 
calculated through 11 ( ( , W,SD ))tdtω ϑ pi++ − . The patient might develop some symptoms with 
probability (SD | , W)tQ s+ when she is in state s. If the patient is in the cancer free state and 
develops some symptoms, a follow-up mammogram (or biopsy) reveals her true health status, so 
her belief state occupancy distribution is updated, and the probability of her eventually dying 
from breast cancer is calculated by 11 ( ( , W,SD ))tdtω ϑ pi++ + . If the patient is in cancer states (s=1 or 
2) and develops symptoms, her lifetime breast cancer mortality risk would be ρ2,t (s) . In this case 
she leaves the model. In the second case when the previous action was a mammogram, the 
patient may develop interval cancer in the current epoch or not. Similar to the first part, the 
corresponding lifetime breast cancer mortality risks for this case is calculated. 
3.3 Numerical Studies 
A wide range of routine screening policies and two-phase policies (with changing screening 
intervals) are evaluated in this section. Policies are defined as a quintuple (starting age, first 
screening interval, switching age, second screening interval, stopping age). For example, policy 
(40,1,50,2,80) represents a policy that recommends women start getting mammograms at age 40 
and undergo the screening test every year up to age 50 and then undergo mammogram every 2 
years up to age 80. Another example for routine screening policy would be (50,1,n,n,100) that 
recommends women undergo annual screenings from age 50 to 100. Table 3-1 provides polices 
considered in the analysis. The earliest screening start age considered is 40 since it is the earliest 
age among the current screening guidelines. We also include the USPSTF policy and no 
mammogram policy in our analysis. In total we evaluate 362 policies. Note that the numerical 
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examples presented in this section do not include six-month policies (i.e., screening every six 
month) because the data source for estimating patient adherence discussed in Section 3.1 does 
not include six-month policies. However, the six-month decision epoch in our model formulation 
allows better representation of disease natural progression. The readers can evaluate more 
policies of interest if they have data for estimating patient adherence behaviors. Different 
adherence cases are also presented as numerical examples in this section.    
Table  3-1 Screening policies considered in the numerical analysis* 
Policy Parameter Range Evaluated 
Start age 40,45,50,55 
First screening interval 1,2,3 
Switch age 50,60,70 
Second screening interval 1,2,3 
Stop age 80,85,90,95,100 
*Two special policies “No mammography” and “USPSTF” policies are also included in the 
numerical analysis but are not shown in the table. 
3.3.1 Model Inputs 
As discussed in Chapter 2, a patient’s level of adherence can be approximated based on her 
personal attributes such as socio-demographic, health, behavioral and knowledge related 
characteristics [29-31]. Three different adherence cases are evaluated in this study: a specific 
woman, the general population, and a perfect adherence case. Adherence probabilities for these 
three cases are extracted using the 2003 Health Information National Trend Survey (HINTS) 
data and the developed design-based logistic regression in Chapter 2. The three adherence cases 
considered in this study are:  
1) A white unemployed woman who is not married and does not have a family history of breast 
cancer and believes she has a low chance of developing breast cancer. This case represents 
very low adherence.  
 51 
 
2) The general population. This case represents the average adherence rate of the U.S. 
population derived from the HINTS data, which is a nationally-representative stratified 
survey. For this case we adjust our logistic regression model for patients’ ages.  
3) Perfect adherence for which a patient adheres to a prescribed mammogram test with 
certainty.  
Table 3-2 shows the confidence intervals of adherence probabilities for the general population 
(Case 2). These results are consistent with the CDC report for 2-year interval between 2008 and 
2010 [32]. As expected, adherence probabilities are increasing in age until late 60’s and then 
start to decrease. This decrease can be related to morbidity and aging associated diseases in older 
ages.  Adherence probabilities for Case 1 are significantly lower than those of Case 2.  For 1-
year screening interval, the highest adherence probabilities appear in ages 65-69 (confidence 
interval (0.0581, 0.2226)), with lowest in ages 40-44 (confidence interval (0.0240, 0.0906)).  
Adherence is only slightly better for 2-year and 3-year screening intervals.  Summary of these 
numbers is omitted for brevity.   
 Table  3-2 Confidence interval of adherence probabilities for the general population (Case 2) 
Age  1-year Interval 2-year Interval  3-year Interval  
40-44 (0.4018, 0.5007) (0.5383, 0.6362) (0.5539, 0.6512) 
45-49 (0.4667, 0.5680) (0.6746, 0.7656) (0.6914, 0.7385) 
50-54 (0.5440, 0.6490) (0.7078, 0.7998) (0.7204, 0.8109) 
55-59 (0.5968, 0.7067) (0.7466, 0.8398) (0.7579, 0.8493) 
60-64 (0.5723, 0.6945) (0.6863, 0.7972) (0.7043, 0.8127) 
65-69 (0.6033, 0.7302) (0.6982, 0.8138) (0.6983, 0.8138) 
70-74 (0.5629, 0.6972) (0.6365, 0.7638) (0.6365, 0.7638) 
>75 (0.4006, 0.5012) (0.5256, 0.6256) (0.5391, 0.6386) 
Initial belief states (risks of early and invasive cancers) for women aged 40 are estimated using 
the Gail model [33]. The Gail model estimates the invasive breast cancer risk for an individual 
based on some risk factors such as age, age at menarche, age at first live birth, number of first-
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degree relatives with breast cancer, etc. To estimate the in situ cancer risk, Gail et al. [34] 
proposed using the incidence ratio between in situ and invasive cancers. For example, for 
average population, the initial risk of early and advanced cancer at age 40 is 0.3% and 0.6%, 
respectively. For the policies with start age greater than 40, the initial belief states are updated 
using the belief states for women at age 40, and Equations 3-3a and 3-3b. 
Table 3-3 presents the data source for our numerical analyses. To specify the post-cancer life 
expectancies we use age-specific mortality rates for patients under cancer treatment from the 
SEER data [35] based on the method described in Arias et al. [25]. To adjust the life 
expectancies for symptomatic cancers, we use the relative hazard rates presented in Wishart et al. 
[26]. 
Table  3-3 Input data sources for model parameter estimation 
Parameter Reference 
Transition probabilities Maillart et al. [18], and Epstein et al. [2] 
BSE sensitivity and specificity  Baxter [38] 
Mammography sensitivity and specificity Maillart et al. [18] 
Lump sum rewards for screen detected cancers SEER [35], and Arias et al. [25] 
Lump sum rewards for symptomatic cancers SEER [35], Arias et al. [25], and Wishart et al.[26] 
Immediate rewards Sonnenberg and Beck [36], and Stout et al. [37] 
Initial risk of early and advanced breast cancer Gail model [33], and Gail et al. [34] 
Interval cancer rate Croteau et al. [7]  
Lifetime breast cancer mortality risk under 
treatment for screen detected cancers 
Schairer et al. [39] 
Lifetime breast cancer mortality risk under 
treatment for symptomatic cancers 
Schairer et al. [39], and Wishart et al. [26] 
Adherence Probabilities Madadi et al. [29], and HINTS [40] 
 
The expected immediate reward for the case the woman waits and no symptom is developed, i.e., 
( , W,SD )tr s − is determined using the half-cycle correction method [36] which assigns 0.5 (six 
months) life years if the patient is alive in the current decision epoch and 0.25 life years if the 
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patient dies in the current decision epoch. The immediate rewards for the other cases are 
calculated using Equation 3-5 and the numbers reported in Stout et al. [37]. 
3.3.2 Results 
3.3.3 Analyses on QALYs 
Table 3-4 presents the top five policies for the three different adherence cases in terms of 
QALYs. It also presents the associated lifetime breast cancer mortality risk for each policy. 
Table  3-4 The five best policies for different adherence cases in terms of QALYs 
Policy QALYs Lifetime BC mortality risk 
Case 1- A Specific Woman 
(40,1,n,n,95) 37.4439 0.0263 
(40,1,n,n,100) * 37.4439 0.0263 
(40,1,n,n,90) 37.4429 0.0264 
(40,1,n,n,85) 37.4405 0.0267 
(40,1,n,n,80) 37.4371 0.0276 
Case 2- General Population 
(40,1,n,n,95) 37.5307 0.0256 
(40,1,n,n,100) 37.5307 0.0256 
(40,1,n,n,90) 37.5306 0.0256 
(40,1,n,n,85) 37.5268 0.0258 
(45,1,n,n,95) 37.5240 0.0264 
Case 3- Perfect Adherence  
(40,1,70,2,90) 37.5252 0.0262 
(40,1,70,2,95) 37.5252 0.0262 
(40,1,70,2,100) 37.5249 0.0262 
(40,1,60,2,90) 37.5205 0.0275 
(40,1,60,2,95) 37.5205 0.0274 
*Policy in bold refers to the ACS policy. 
The best policies for both Case 1 and the general population include the ACS policy. However, 
Case 1 has lower QALYs and higher breast cancer mortality risk comparing to the general 
population due to lower adherence probabilities. The best policies for the perfectly adherent case, 
however, does not include the ACS policy and prescribe less frequent mammograms (2 year 
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interval) at older ages. For very frequent policies (e.g., the ACS), the imperfect adherence cases 
benefit more. Note that the USPSTF policy is not among the best policies for any of the 
adherence cases presented above.   
Evaluation of the impact of adherence behavior on the outcomes of a specific screening policy 
shows that higher adherent women always have lower breast cancer mortality risk. However, this 
does not apply to the QALYs; for some policies Case 2 with imperfect adherence behavior have 
higher QALYs than perfect adherent women (Case 3).   Let	∆<%	denote the percent of QALYs a 
woman in the adherence Case 	= 1,2 loses due to her imperfect adherence to the prescribed 
screening policy	, i.e., 
∆ = sc] − sc] sc] ,  = 1,2 3-8 
where sc]  is the QALYs of policy  for Case 3, a perfectly adherent woman. Figure 3-3 
shows 29 policies that have negative losses, implying that women with average adherence as the 
general population (Case 2) benefit more than perfectly adherent women.  Note that for all the 
policies considered in this study, Case 1 always has the lowest QALYs and thus positive values 
of ∆<% for all policies. 
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Figure  3-3 QALYs loss due to imperfect adherence 
3.3.4 Analyses on Lifetime Breast Cancer Mortality Risk 
The five best policies in terms of lifetime breast cancer mortality risk, interestingly, are the same. 
These policies are presented in Table 3-5. Note that the calculated breast cancer mortality 
presented here are very close to the CDC estimate of 1 in 37 women (~ 0.027) [41]. Unlike the 
first objective function (QALYs), the breast cancer lifetime mortality risk has a straightforward 
relation to the expected number of prescribed mammograms and the expected number of actual 
mammograms the woman undergoes. In other words, policies with more frequent mammograms 
decrease the risk of dying from breast cancer. The results show that among the adherence cases 
presented here, Case 3 (perfect adherent women) benefits the most and has the lowest risk of 
dying from breast cancer. This implies that, although exposure to mammography X-ray may 
increase women’s risk of developing breast cancer, on average it is not strong enough to affect 
the benefits of mammography examination in deceasing breast cancer lifetime mortality risk. 
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This is in line with a previous study on estimating the risk of radiation-induced breast cancer 
following exposure of the breast to ionizing radiation occurring during mammography tests [9]. 
Table  3-5 The five best policies for different adherence cases in terms of lifetime breast cancer 
mortality risk 
Policy Lifetime breast cancer 
mortality risk  QALYs 
Case 1- A Specific Woman 
(40,1,n,n,100) 0.0263 37.4437 
(40,1,n,n,95) 0.0263 37.4439 
(40,1,n,n,90) 0.0264 37.4429 
(40,1,n,n,85) 0.0267 37.4405 
(40,2,50,1,100) 0.0273 37.4193 
Case 2- General Population 
(40,1,n,n,100) 0.0256 37.5304 
(40,1,n,n,95) 0.0256 37.5307 
(40,1,n,n,90) 0.0256 37.5306 
(40,1,n,n,85) 0.0258 37.5268 
(40,2,50,1,100) 0.0273 37.5214 
Case 3- Perfect Adherence  
(40,1,n,n,100) 0.0242 37.5013 
(40,1,n,n,95) 0.0242 37.5025 
(40,1,n,n,90) 0.0242 37.5044 
(40,1,n,n,85) 0.0244 37.5033 
(45,1,n,n,100) 0.0249 37.5172 
 
3.3.5 Efficient Frontier Policies and Policies in General Practice 
Table 3-6 presents the results for policies in general practice and no mammography policy for 
the three adherence cases.  
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Table  3-6 QALYs and, mortality risk for screening policies in general practice 
Policy 
Case 1- A Specific 
Woman 
Case 2-General 
Population 
Case 3- Perfect 
Adherence 
QALYs Mortality QALYs Mortality QALYs Mortality 
ACS* 37.4437 0.0263 37.5304 0.0256 37.5013 0.0242 
USPSTF 37.2772 0.0362 37.3890 0.0348 37.4255 0.0339 
Every 2 Years*  37.3585 0.0313 37.4756 0.0299 37.5107 0.0289 
Every 3 Years* 37.3066 0.0347 37.4091 0.0334 37.4514 0.0327 
No mammography  37.0142 0.0527 37.0142 0.0527 37.0142 0.0527 
* Screening start age and end age for this policy is 40 and 100, respectively.  
As the results in sections 3.2.1 and 3.2.2 suggest, there is a tradeoff between the two objective 
functions. Figure 3-4 provides all policies (excluding “no mammogram” policy) along with the 
lists of efficient policies for each adherence cases. The efficient policies, ACS and USPSTF 
policies are highlighted in Figure 3-4. The screening starting age for all efficient policies (except 
for the perfect adherence case) is 40. It is in contrary to the earlier study [42] in which the author 
argues that the benefits for women younger than 50 are less certain because of the lower 
incidence of the disease. However, since disease progression rate is higher and the cancer 
sojourn time is shorter in women younger than 50, benefits of getting screened before age 50 is 
justifiable [43].  
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Policies QALYs BC 
Mortality 
Risk 
 
Case 1- A Specific Woman 
(40,1,n,n,95) 
(40,1,n,n,100) 
37.4439 
37.4439 
0.0263 
0.0263 
 
 
 
 
   
   
   
   
Case 2- General Population 
(40,1,n,n,95) 
(40,1,n,n,100) 
37.5307 
37.5307 
0.0256 
0.0256 
 
Case 3- Perfect Adherence  
(40,1,n,n,90) 37.5044 0.0242 
 
(45,1,n,n,90) 37.5202 0.0250 
(45,1,n,n,95) 37.5183 0.0249 
(40,1,70,2,90) 37.5252 0.0262 
(40,1,70,2,95) 37.5252 0.0262 
Figure  3-4 Efficient frontier policies for the three adherence cases 
37.10
37.15
37.20
37.25
37.30
37.35
37.40
37.45
37.50
37.55
37.60
0.0235 0.0285 0.0335 0.0385
QALYs
Lifetime BC Mortality Risk
ACS
USPSTF
37.10
37.15
37.20
37.25
37.30
37.35
37.40
37.45
37.50
37.55
37.60
0.0230 0.0280 0.0330 0.0380
QALYs
Lifetime BC Mortality Risk
ACS USPSTF
37.10
37.15
37.20
37.25
37.30
37.35
37.40
37.45
37.50
37.55
37.60
0.0230 0.0280 0.0330 0.0380
QALYs
Lifetime BC Mortality Risk
ACS
USPSTF
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The current ACS policy (listed in bold in Figure 3-4) is only efficient for Case 1 and Case 2. For 
perfect adherence case, efficient frontier policies are similar to the ACS with one year interval 
between subsequent tests but smaller ending age. Note that, the USPSTF policy and other 
policies in general practice (for which the associated QALYs and breast cancer lifetime mortality 
risk are presented in Table 3-6) are not among the efficient policies for any of the adherence 
groups.  
It can be seen that there are more efficient policies for the perfect adherence case compared to 
the other two cases. This occurs because of the tradeoff between the two objective functions. For 
the perfect adherence case, the first objective (QALYs) requires less frequent mammograms due 
to disutility of mammogram tests and perfect compliance of this case with the prescribed policies. 
On the other hand, the second objective (lifetime breast cancer mortality risk) requires more 
frequent mammography tests to have a lower risk of dying from breast cancer. Therefore, for this 
case the efficient policies are more spread out. For the other two adherence cases, since women 
are more likely to skip a prescribed mammogram, the first objective requires more frequent 
mammograms (every year) to compensate for the skipped mammograms. Thus, we have fewer 
efficient policies for these cases.  
The tradeoff plots presented in Figure 3-4 are more spread for the perfect adherence case and 
gets denser and less spread as the adherence level decreases. This happens because as the 
adherence level decrease, policies converge to “no mammogram” policy with associated QALYs 
and lifetime breast cancer mortality risk of 37.0142 and 0.0527, respectively. 
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3.4 Conclusion 
Current screening mammography guidelines assume that women’s compliance with the 
recommendations is perfect, i.e., women undergo their mammograms as prescribed by their 
physicians/health providers. However, this is not the case in reality. Women skip mammograms 
for different reasons. This study investigates the effect of imperfect adherence for a wide range 
of screening mammography policies. Two different method of breast cancer detection are 
considered: mammography examination and self-detection. We also incorporate the possibility 
of detecting breast cancer within 12 months after a normal mammography screening (interval 
cancer), and the risk of developing radiation-induced breast cancer during mammography 
examination. A randomized partially observable Markov chain is proposed to evaluate and 
compare various screening policies and current practices in terms of two important health 
outcomes: quality adjusted life years (QALYs), and the lifetime mortality risk of breast cancer 
while incorporating women’s adherence behavior to mammography guidelines. 
Three different adherence cases are considered, including perfect adherence and two imperfect 
adherence cases. The adherence probabilities for imperfect adherence cases are estimated using a 
woman’s characteristics (e.g., age, race, marital status, perception of breast cancer risk, etc.). Our 
results indicate that depending on the policy under study, there is one adherence group that 
benefits the most in terms of QALYs. As the policies get more intense (more frequent policies), 
the general population case obtains higher QALYs comparing to the perfect adherence case. 
However, Case 1 (a specific woman), which has a very low adherence level, always has lower 
QALYs than the other two cases. In terms of lifetime breast cancer mortality risk, higher 
adherence cases experience lower mortality risk for all policies. A set of efficient frontier 
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policies are extracted for different adherence cases. The ACS policy was among the efficient 
frontier policies for the two imperfect cases, but not for the perfect adherence case. Comparing 
efficient frontier policies for different adherence cases indicates that on average women with 
higher level of adherence experience higher QALYs, lower lifetime breast cancer mortality risk 
and longer interval between two subsequent prescribed mammograms. 
The outcomes of this chapter along with the results of Chapter 2  can help physicians/health 
providers to tailor screening mammography recommendations based on their patient’s estimated 
adherence likelihood. In other words, based on the patient characteristics and estimated 
adherence level, physicians can decide if they should shorten or lengthen the interval between 
two subsequent mammograms. 
The direction for our future research is to incorporate the risk behavior of the decision maker and 
explore how different risk attitudes (risk averse, risk seeking) along with adherence behavior 
may affect a policy’s efficiency. In this study, our purpose is to evaluate the impact of adherence 
on patient outcomes.  Another possible direction is to optimally find a screening policy based on 
the patient estimated adherence behavior. It seems that screening adherence may be a function of 
a woman’s screening history; i.e., a woman with better screening history are more likely to 
adhere to the current screening recommendation. Although our study considers the screening 
history in estimating adherence probabilities based on a survey data, it does not incorporate the 
dynamic feature of this factor. In addition, adherence strongly depends on a patient’s experience 
in her previous screenings (e.g., false positives). We do not include these factors in our study due 
to lack of data with regard to these characteristics. 
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 Minimizing Overdiagnosis in Breast Cancer Screening 4
4.1 Introduction 
In Chapter 3, the potential benefits and risks associated with screening mammography are 
discussed. Unreliability of screening examinations, increased risk of radiation-induced cancer, 
and overdiagnosis are among the potential risks of screening. Overdiagnosis is known to be the 
most important disadvantage of cancer screening [1] as it can adversely affect people’s lives. 
Overdiagnosis is defined as the diagnosis of screen-detected cancers that would not have 
presented clinically in a woman’s lifetime in the absence of screening [2]. Overdiagnosis causes 
physical, psychosocial and economic harms by unnecessary labeling of patient with a lifelong 
diagnosis as well as unneeded treatments and surveillance [3].  
There are two possible explanations for overdiagnosis: 1) The cancer never progresses (or, in 
fact, regresses), or 2) the cancer progresses slowly enough that the patient dies from a competing 
cause before the cancer becomes symptomatic [3]. In other words, overdiagnosis occurs when 
"very slow" growing cancers (more precisely, at a slow enough pace that individuals die from 
something else before the cancer ever causes symptoms) are detected. The second explanation 
incorporates the interaction of three factors: the tumor size at detection, its growth rate, and the 
patient’s competing risks for mortality. Thus, even a rapidly growing cancer may still represent 
overdiagnosis if detected when it is very small or in a patient with limited life expectancy [4].  
Note that overdiagnosis is different from false positive. Overdiagnosis occurs when a disease is 
diagnosed correctly, but the diagnosis is irrelevant suggesting that the treatment for the disease 
is not needed. However, false positive is an initial test result that suggests the presence of a 
disease, but it is later proved (with additional testing) that the disease is not present. 
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As it is not possible to distinguish between lethal and harmless cancers, all detected cancers are 
treated. Overdiagnosis and overtreatment are therefore inevitable [5]. However, tailoring 
screening strategies can control the probability of overdiagnosis, and thus decrease the cost 
associated with overdiagnosis and overtreatment. 
Quantifying overdiagnosis, however, is challenging because it is impossible to distinguish 
between an overdiagnosed cancer and one that will become clinical at the time of diagnosis. 
There are various studies that quantified overdiagnosis resulting from cancer screenings. The 
magnitude of overdiagnosis estimates varies widely from one study to another. For example, 
according to Welch and Black [2], 25% of mammographically detected breast cancers are 
overdiagnosed. However, based on Jørgensen & Gøtzsche [4], one in three breast cancers 
detected in publicly organized mammography screening programs is overdiagnosed. Biesheuvel 
et al. [6] provided a very rough estimate of overdiagnosis, ranging from around 3 to 50% or more. 
In an earlier study in 2008, Duffy et al. [7] estimated the breast cancer overdiagnosis risk to be 
39%. However, in a later study [8] after a prolonged follow-up of a screening program in 
England and Wales, Duffy and Parmar reported an overdiagnosis risk of 7–8% for a biannual 
screening schedule. They found this estimate to be considerably more plausible than their own 
previous estimate of 39%. Carter et al. [9] conducted a systematic review on overdiagnosis 
studies, and identified the methods that have been used for measuring overdiagnosis of cancer. 
They analyzed the advantages and disadvantages of each method in providing reliable estimates 
of overdiagnosis. 
Most of the studies mentioned above are cohort studies or randomized controlled trial follow-up 
studies which estimate the overdiagnosis risk based on the changes in breast cancer incidence 
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following the introduction of screening programs in a population setting [4-8]. However, the 
downside of these studies is the substantial time and resource requirements due to the need for 
follow-up observations over a long period of time in order to get a reliable overdiagnosis 
estimate. Another approach in estimating overdiagnosis is through mathematical modeling. 
There are a few relevant studies in the literature that propose a mathematical framework for 
estimating overdiagnosis risk [10-12]. Davidov et al. [10] developed a mathematical model to 
evaluate the probability of overdiagnosis for cancer screening. They applied their model to 
hypothetical early detection programs for prostate cancer. Gunsoy et al. [11] developed a 
Markov simulation model for the evaluation of mammography screening in a cohort of British 
women born in 1935-40. They evaluated the impact of the screening frequency, starting and 
ending ages on breast cancer mortality reduction and overdiagnosis. Seigneurin et al. [12] 
developed a stochastic simulation model and an approximate Bayesian computation approach to 
quantify overdiagnosis.  
In this chapter, we propose a mathematical framework to estimate breast cancer lifetime 
overdiagnosis and mortality risks for different screening policies. In addition, we propose an 
optimization model to minimize lifetime risk of overdignosis of breast cancer while maintaining 
a patient’s lifetime breast cancer mortality risk at a predefined level. Our model provides a more 
flexible framework for modeling different uncertainty sources such as cancer sojourn time. 
Cancer sojourn time is defined as a time interval between the onset of a detectable preclinical 
cancer and the point when the cancer progresses to the clinical stage, causing signs and/or 
symptoms [13]. In addition, different from previous studies, we seek for the optimal screening 
policy that yields the minimum lifetime overdiagnosis risk.  
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The remainder of this chapter is organized as follows. In Section 4.2, the proposed model is 
presented. Section 4.3 presents the data sources and parameters estimation for our numerical 
studies. In Section 4.4, some mammography screening policies are evaluated and (near) optimal 
policies are obtained. Finally, Section 4.5 summarizes the findings and concludes this chapter.  
4.2 Proposed Model 
In the proposed model, we incorporate uncertainty in the onset of detectable preclinical cancer, 
variation in the cancer sojourn time, and competing causes of death. Our goal is to find the 
optimal breast cancer screening policies that minimize the overdiagnosis risk which is defined as 
the probability of detecting a cancer that would never develop symptoms or cause death during 
the patient’s lifetime in the absence of screening. The model also maintains the lifetime breast 
cancer mortality risk at a predefined threshold. Following is the list of notation used in the 
problem formulation. 
m number of screening examinations in the prescribed policy 
? screening schedule,? ={?, … , ?9},where ?’s are the decision variables 
representing the age at which a mammogram should be prescribed. We denote the 
beginning and ending of the decision period with ?y and	?9, respectively. Note 
that ?y and ?9 are not decision variables and just represent the decision 
horizon. 
\ random variable representing the patient’s age at the onset of the detectable 
preclinical cancer 
E random variable representing the cancer sojourn time  
E  random variable representing the remaining sojourn time (also known as forward 
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recurrence time) measured from age ?  
X patient health state space, X = {L, EL, LL}, where L, EL, LL represent a cancer-
free individual, a patient with screen detected breast cancer, and a patient with 
clinical (symptomatic) breast cancer, respectively. 
I random variable representing the life years of an individual in health state  ∈ X 
I  random variable representing the remaining life years of a patient in health state  ∈ X at age ?  
.  probability density function of  \ 
.  probability density function of the cancer sojourn time when the cancer 
preclinical onset is in the !" screening interval [?, ? 
 |.  probability density function of the forward recurrence time measured from age  ? 	given that the cancer preclinical onset (\) is in the !" screening interval 
[?, ? 
ℎ|.  conditional probability density function of  I  ,	the remaining life years of an 
individual in health state  given that she has survived to age   
H|.  conditional cumulative distribution function of I  ,	the remaining life years of an 
individual in health state  given that she has survived to age    
  
  
C  sensitivity of mammography (probability of detecting a cancer when it is present) 
at age ?  
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4.2.1 Overdiagnosis 
The objective of the model is to minimize the probability of breast cancer overdiagnosis, i.e., the 
probability of detecting a cancer through screening that would never develop symptoms or 
causes death during a patient’s lifetime. Figure 4-1 shows the case when overdiagnosis occurs.  
 
 
 
 
 
 
Figure  4-1 Representation of overdiagnosis in cancer screening 
 
In the case of overdiagnosis, the breast cancer is detected through a screening examination and 
treatment starts upon cancer detection. However, if the breast cancer was not detected through 
screening, the patient would have died from a competing cause before the breast cancer grows to 
the clinical stage. In other words, the cancer grows slowly enough that the patient would die 
from a cause other than breast cancer before the cancer became symptomatic. Therefore, the 
probability of overdiagnosis is equivalent to the conditional probability that at the time of cancer 
detection (? , the remaining cancer sojourn time (E ) is greater than the remaining life years of a 
cancer-free individual I , given that the cancer is diagnosed through screening. Suppose F is 
the event that the cancer is detected through screening examinations. Then the probability of 
overdiagnosis is 
Death from other 
causes 
Cancer becoming symptomatic 
in the absence of screening 
Cancer detection 
through screening 
Time 
Onset of 
preclinical cancer 
 
Treatment starts 
Treatment 
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>2E > I F3. 4-1 
Let [ ∈ [?, ?,  = 1, 2, … ,, be the onset of the detectable preclinical breast cancer. Given 
that the cancer is diagnosed at the !"screening (at age	? ,  = ,  + 1,… ,), the conditional 
probability of overdiagnosis is 
 [ =    |], [ℎ| >>]yy 																						
=   |], [H| ]],y  
4-2 
which calculates the probability that the remaining sojourn time is greater than the remaining life 
years of a cancer-free individual at age ? . Note that the remaining life years of a cancer-free 
patient is independent of the cancer onset and remaining sojourn time. The upper bound of the 
remaining sojourn time is infinity (+∞) implying that it is possible that the cancer would never 
advance to the clinical stage or produce symptoms. In addition, the conditional probability 
density function of the cancer sojourn time (. ) and the conditional probability density 
function of the forward recurrence time (the remaining sojourn time,	 |. ) are related through 
the following equation.  
 
 |], [ = >2E = ? − [ + ]E > ? − [3 = 2? − [ + ]3̅2? − [3 , ∀] > 0 4-3 
 
where ̅.  is the survival function of the cancer sojourn time when the cancer onset is at 
[ ∈ [?, ?.  
In addition, diagnosing the cancer at age ?  through screening implies that the cancer has not 
become symptomatic yet. Let  [ be the probability that a cancer with onset [ ∈ [?, ? has 
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not developed to a clinical stage at age ? 	yet (i.e., the cancer sojourn time is greater than	? − [, 
Figure 4-2), given that the cancer sojourn time is greater than	?  − [, i.e., 
 [ = >2E > ? − [3>2E > ?  − [3 = ̅2? − [3̅2?  − [3 ,  > .			 4-4 
 
Note in the case that  = ,  [ reduces to >E > ? − [. 
 
 
 
 
 
Figure  4-2 Representation of a hypothesized screening policy, cancer onset and detection 
 
Let F  be the event that the cancer is diagnosed at the !" screening when the onset of the 
detectable preclinical cancer is in the !" screening interval.  This implies that the cancer was 
missed in all previous screenings (!",  + 1!", … ,  − 1!", and then detected at the !" 
examination which occur with probability  
>2F 3 = 
C 																					 = ,
C 1 − C@−1@=  > . 4-5 
Moreover, assume that F is the event that the cancer is diagnosed through screening given that 
its preclinical onset is in the  screening interval. Then, F 	= ⋃ F 9  , and F   ] are mutually 
?  
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Detection 
? ?T ? … ? … ?  
? − [ 
Symptomatic 
Cancer  
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exclusive events. Therefore, the probability that a cancer with preclinical onset in the !" interval 
is diagnosed through screening is	 
>F =+>2F 39  . 4-6 
Hence, following is the probability of overdiagnosis given that the cancer onset is at [ ∈
[?, ? 
[ =+ [9   [	>2F 3>F . 4-7 
In addition, given that the patient develops breast cancer in her lifetime, the probability that the 
cancer onset is in the screening interval [?, ? is ¡ ¢!£!¤¥¤¥¦§: , where is the lifetime probability 
of developing breast cancer and  = ¡ [[.¨©ª§y  Therefore, since cancer onset at different 
intervals are mutually exclusive, the probability of overdiagnosis for screening schedule 
? = {?, ?T, … , ?9} is  
«¨ = 1+ [[[¨¥¨¥¦§
9
 															 																																																									
= 	 1++>2F 3>F  [¨¥¨¥¦§
9
   [  ], [H| ]	][

y .
9
  
4-8 
 
4.2.2 Lifetime Breast Cancer Mortality Risk 
To calculate the lifetime breast cancer mortality risk, two cases need to be considered: i) when 
the cancer is diagnosed through screening examination, and ii) when the cancer progresses to a 
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clinical stage and becomes symptomatic in the interval between two prescribed screening tests. 
These two distinct cases are considered because symptomatic cancers, as opposed to screening 
detected cancers, are more advanced and may lead to higher breast cancer mortality risk [14]. 
Suppose that the cancer preclinical onset is in the !"	prescribed screening interval, i.e. \ = [ ∈
[?, ?. The lifetime cancer mortality risks for these two cases are discussed below. 
Consider the first case when the cancer is diagnosed at age ?  or the !" screening test ( ≥ . In 
this case the probability that the patient dies from breast cancer is 
¬ , = >2I ­ < I 3 =  ℎ| >H­| >y >. 4-9 
 
Given that the cancer is detected at the !" screening test, the patient should survive to age ? . 
The probability that the patient does not die from other causes before age ? 	given that she has 
survived to age ?  is  
2I > ? 32I > ? 3. 4-10 
 
Detecting the cancer at the !" screening test implies that the cancer sojourn time is greater than 
? − [.	This is also suggesting the cancer does not develop any symptoms up to age 	? . The 
associated probability of this event as presented in Equation 4-4 is  [ = ®̅¥2¨8!3®̅¥2¨8¦§!3. 
In addition, the probability that the cancer is diagnosed at the !"screening is presented in 
Equation 4-5. Therefore, using the total probability rule the unconditional probability that a 
screen detected cancer causes death is  
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+¬ , I > ? I > ?   [>2F 3
9
  . 4-11 
Since cancer onset at different intervals are mutually exclusive, using the total probability rule, 
the lifetime breast cancer mortality risk for the first case is 
K¨, =++>2F 3 I > ? I > ?  ¬ , [ [[¨¥¨¥¦§
9
 
9
 . 4-12 
 
The second case considers a situation in which the cancer becomes symptomatic. Assume that 
the cancer becomes symptomatic at age u	∈ 2? , ? 3,  =  + 1,… ,. Given that the cancer has 
not been detected up to age	? , the probability that the cancer becomes symptomatic at age u in 
the interval between ?  and ?  is 
T[, ¯ = °¥±®̅¥¨8¦§!. 4-13 
In this case, the conditional breast cancer lifetime mortality risk at age ¯ is  
¬ ,T¯ =  ℎ|±> ∙ H|±>y >. 4-14 
Similar to the first case, the probability that the patient does not die from a competing cause 
given that she has survived to age ?  (when she received a false negative screening result) is 
I > ¯2I > ? 3. 4-15 
Therefore, the associated cancer mortality risk when the cancer onset is in the interval [?, ?, 
and the cancer becomes symptomatic at age ¯ in the interval 2? , ? 3,  =  + 1, … is 
1− C³ ³  2[, ¯ ´I
L > ¯µ´IL > ?−1µ??−1 ¬,2¯	¯, 4-16 
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which calculates the probability that the cancer does not get detected through previous 
screenings (∏ 1 − C³ ³ 	and the probability that the individual dies from breast cancer when 
the cancer becomes symptomatic in the interval ? , ? . Summing over all screening intervals 
after the cancer onset interval, the cancer mortality risk is  
 
·[ = + 1 − C³ ³  T[, ¯ I
 > ¯2I > ? 3¨8¨8¦§ ¬ ,T¯	¯
9
  . 4-17 
 
In addition, it is possible that the cancer becomes symptomatic before the first scheduled 
screening in the interval [, ?. In such a case, the following is the associated cancer mortality 
risk, which has a similar logic as Equation 4-17.  
·T[ =  ¯ I > ¯2I > ? 3¨¥! ¬ ,T¯	¯ 4-18 
Equation 4-18 calculates the probability that the cancer becomes symptomatic at age ¯	¯, 
the patient does not die from a competing cause in the interval (? , ¯, i.e., ¸2¹º»¼±3¸2¹º»¼¨8¦§3, and she 
eventually dies from cancer (¬ ,T¯). 
Similar to the first case, since cancer onset at different intervals are mutually exclusive, the 
lifetime cancer mortality risk of screening schedule ? for a symptomatic cancer is  
K¨,T =+ [[·[ + ·T[]¨¥¨¥¦§ [
9
 . 4-19 
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Considering both cases of cancer detection, the lifetime cancer mortality risk for schedule ? is  
½¨ = K¨, + K¨,T. 4-20 
Optimization Model 
The proposed optimization model can then be written as  
Min	«¨  Min	  
s.t.  ½¨ < ¿ 4-21 ? < ?    ∀ 4-22 ? ∈ {?y, ?y + δ, ?y + 2δ… , ?9 − δ} ∀,	 4-23 
 
where constraint 4-21 ensures that the lifetime mortality risk is less than a predefined threshold; 
constraints 4-22 and 4-23 determine the order of screening decisions and age range in which the 
screening tests should be prescribed, respectively. ?y and ?9	in equation 4-23 represent 
starting and ending age of a screening schedule. In addition, δ in constraint 4-23 represents the 
minimum interval between two subsequent screening tests. 
4.3 Model Inputs 
Table 4-1 presents the summary of data sources for the different inputs (parameters and 
probability distributions) incorporated in the model.  
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Table  4-1 Data sources for the model input estimations 
Description Reference 
Distribution of onset of preclinical detectable 
breast cancer 
 Parmigiani and Skates [15] 
Parameters of preclinical sojourn time distribution 
(exponential case) 
Shen and Zelen [16] 
Tabar et al. [17] 
Parameters of preclinical sojourn time distribution 
(lognormal case) 
Peer et al. [21] 
Probability density of remaining life years of a 
cancer-free individual 
The US life table for females (Center for 
Disease Control and Prevention) [22] 
and Surveillance, Epidemiology and 
End Results (SEER)  [23] 
Age and stage specific probability distribution of 
death from breast cancer 
Schairer et al. [24] and Zhang [25]  
Stage distribution of screen detected breast cancers Bleyer and Welch [26] 
Stage distribution of clinically detected breast 
cancers 
Plevritis et al. [27] 
Age specific mammography sensitivity Kerlikowske et al. [28] 
The probability distribution of breast cancer onset is the most challenging distribution in this 
study to estimate. Parmigiani and  Skates [15] developed a convolution model to estimate the age 
of disease onset distribution based on the natural history of disease and the data available on 
disease incidence rate, cancer sojourn time, competing causes of death, etc. They then used 
singular value decomposition method to solve their developed model numerically. We applied 
their method to estimate breast cancer preclinical onset age distribution in this study. Figure 4-3 
shows the extracted probability density for the preclinical breast cancer onset. 
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Figure  4-3 Estimated distribution of the age of onset of detectable breast cancer 
There are various studies in the literature estimating the distribution of breast cancer sojourn time. 
Some of these studies used exponential specification in estimating the sojourn time distributions 
[16-19]. However, the assumption of exponential duration in the preclinical stage has some 
limitations. The first concern is the implausible assumption of mode at zero, which corresponds 
to an instant transition from preclinical to clinical stage, and the fast decaying tail, which does 
not adequately account for slow growing tumors [15]. The second limitation is due to the 
memoryless property of the exponential distribution, which implies that the sojourn time and 
remaining sojourn time upon cancer detection through screening have the same distribution. In 
other words, the hazard function of sojourn time is constant, implying that as time passes the 
instantaneous probability that the cancer develops to a clinical stage is constant. However, it 
would be more plausible that the instantaneous probability of developing to a clinical stage 
increases with time. A second distribution proposed for modeling cancer sojourn time is 
lognormal distribution. Spratt et al. [20] postulated a lognormal distribution for sojourn time 
based on the growth patterns of breast tumors. In this study, we examine both exponential and 
lognormal sojourn time distributions.  
0
0.0005
0.001
0.0015
0.002
0.0025
0.003
0.0035
0.004
40 43 46 49 52 55 58 61 64 67 70 73 76 79 82 85 88 91 94 97 100
Probability
Age
 81 
 
For the exponential case, the age-specific rate parameters are adopted from the mean sojourn 
time provided in Shen and Zelen [16], and Tabar et al. [17]. Figure 4-4 presents the estimated 
exponential breast cancer sojourn time distributions for the different age groups: 40-49, 50-59, 
and 60 and older. It also presents the corresponding hazard function for different age groups.  
For the case with lognormal sojourn time, the age-specific distribution parameters are estimated 
using the median and upper 95% quantile matching Peer et al. [21]. The estimated lognormal 
breast cancer sojourn time distributions for the three age groups, along with the corresponding 
hazard functions are presented in Figure 4-5. As the results show, the hazard functions for this 
case are increasing for most parts. However, for the first and second age groups, the hazard rate 
starts decreasing very slowly for after about three years and five years, respectively. This 
suggests that if no symptom appears by a certain amount of time after the cancer onset, then the 
instantaneous probability that the cancer actually becomes symptomatic starts to decrease 
(because the tumor stops growing or it regresses). 
The probability distribution of the remaining life years for a cancer-free individual is extracted 
from the 2008 US life table for females [22] and the Surveillance, Epidemiology and End Results 
(SEER) data [23]. SEER data is used to exclude the probability of death from breast cancer in the 
life table and adjust the probabilities for women without breast cancer.  
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Figure  4-4 Estimated exponential breast cancer sojourn time distribution for different age groups 
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Figure  4-5 Estimated lognormal breast cancer sojourn time distribution for different age groups 
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We estimate the probability density of remaining life years for the two cases of cancer detection 
(screen detected and symptomatic breast cancer) using the data available in Schairer et al. [24] 
and Zhang [25]. We adopt the stage distributions of screen detected and symptomatic breast 
cancer from Bleyer and Welch [26] and Plevritis et al. [27], respectively, and adjust the 
probability density of remaining life years for the two cases.  
The mortality probabilities in [22, 24-25] are presented in tabular format, and therefore we used 
piecewise-constant density function to model the probability density functions. Let   be the 
probability that an individual of age  in health state  dies in the age interval ,  + 1]. 
Therefore,  
>2I ≤ 3 = 1 −Â 1 −  4-24 
and, 
ℎ |> = >2I ≤  + 13 − >2I ≤ 3>I ≥  ,  < > ≤  + 1,  > . 
 
4-25 
Lastly, age specific mammography screening sensitivities are extracted from Kerlikowske et al. 
[28]. 
4.4 Computational Results 
Disease onset ad conditional remaining life year functions do not have a general closed form and 
are only available in tabular format. This makes analytical calculation of integration very 
challenging or even impossible. Therefore, in this study we exploit Monte Carlo integration 
method to calculate the integrations in the proposed model.  Monte Carlo integration methods are 
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sampling methods to calculate complicated integrations, based on the central limit theorem and 
the law of large numbers. Please refer to Robert and Casella [29] for more details.  
In addition, due to the complexity of the model, solving the optimization model through 
analytical approaches is not feasible. Therefore, we apply a combination of bisection method and 
Particle Swarm Optimization (PSO) method to find the (near) optimal solution of the proposed 
model. 
The results presented in this section have two parts. In the first part we evaluate different 
screening policies, including the ACS and the USPSTF policies, in terms of the breast cancer 
overdiagnosis and mortality risks. The second part presents the (near) optimal policies obtained 
using the bisection and PSO algorithm. 
4.4.1 Policies Evaluation  
In this section we present the overdiagnosis and lifetime mortality risks of different policies for 
two reasons: (1) to validate our model by comparing the obtained risk values with numbers 
reported in the literature, and (2) to evaluate these polices and compare their performance in 
terms of breast cancer overdiagnosis and mortality risks. We evaluate different static as well as 
dynamic screening policies with two and three different screening intervals between subsequent 
tests. Table 4-2 presents the policies evaluated in this chapter. Including the USPSTF policy, in 
total we evaluated 241 policies. We present these policies using the same structure as introduced 
in Chapter 3. For a policy with three different screening intervals, we use a similar structure as 
well. For example, policy (40,1,50,2,60,3,80) recommends women get annual screening tests 
between age 40 to 50, then switch to biennial screenings up to age 60, and finally undergo 
screenings every three years up to age 80. 
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Table  4-2 Screening policies considered in the numerical analysis 
policy Starting 
age 
1st 
interval 
1st switch 
age 
2nd  
interval 
2nd switch 
age 
3rd 
interval Ending age 
Static 40,50 1,2,3 - - - - 80,90,100 
Dynamic with 2 
screening 
intervals 
40,50 1,2,3 50,60,70 1,2,3 - - 80,90,100 
Dynamic with 3 
screening 
intervals 
40,50 1,2,3 50,60,70 1,2,3 60,70,80 1,2,3 80,90,100 
4.4.2 Exponential Sojourn Time 
Figure 4-6 presents the breast cancer overdiagnosis and mortality risks of the policies considered 
in this chapter along with the efficient frontier policies (highlighted) for the case with 
exponential sojourn time.  
 
 
Figure  4-6 Overdiagnosis and mortality risks of the screening policies in Table 4-2 under 
exponential sojourn time 
The overdiagnosis risk estimates for biannual screening schedules are very close to the values 
reported in the literature: Duffy et al.’s estimate of 7%-8% [8], Zackrisson et al.’s estimate of 10% 
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[30], De Gelder estimate of 8.9–15.2% [31] and 7.2% [32]. To the best of our knowledge there is 
no overdiagnosis reported in the literature for annual screening policies. Therefore, we did not 
have a reference to compare our results with. The breast cancer mortality risks are also 
comparable with the mortality risks estimated in Chapter 3 (reported in Table 3-6). Note that, the 
underlying sojourn time distribution for both results in Table 3-6 and Figure 4-6 is exponential.  
The results in Figure 4-6 show that both the ACS and the USPSTF policies are efficient. In fact, 
the USPSTF policy and the ACS policy have the lowest overdiagnosis and mortality risk among 
the evaluated policies, respectively. Most of the efficient frontier policies (except for the ACS 
and (40,1,n,n,90)) recommend women stop screening at or before age 80. This is because after 
age 80, the probability of death from competing causes significantly increases which results in 
high overdiagnosis risk. In addition, most efficient policies (except for the USPSTF and 
(50,1,60,3,80)) recommend women start screenings at age 40. This maintains both the 
overdiagnosis and mortality risks at a lower level. In addition, in terms of the distribution of 
screening tests in the efficient frontier policies, more frequent tests are recommended in the age 
interval 50 to 60 when the breast cancer onset is more likely. 
4.4.3 Lognormal Sojourn Time 
The corresponding overdiagnosis and mortality risks for the case with lognormal sojourn time 
with efficient frontier policies highlighted are presented in Figure 4-7. The overdiagnosis risks 
for this case are very close to the exponential case, and therefore comparable with the reported 
values in the literature [8, 30-32]. Also, the mortality risks are very close to the mortality risk 
estimations reported in Table 3-6 in Chapter 3.  
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Similar to the case with exponential sojourn time, the ACS policy with the highest number of 
screening tests has the highest overdiagnosis and lowest lifetime breast cancer mortality risk and 
the USPSTF, on the other hand has the lowest overdiagnosis risk. In addition, the recommended 
stopping age in most efficient policies is 80 to maintain a low overdiagnosis risk. Similar to the 
exponential sojourn time case, more screening tests are distributed between age 50 to 60 
comparing to the other age intervals. 
 
Figure  4-7 Overdiagnosis and mortality risks of the screening policies in Table 4-2 under 
lognormal sojourn time 
4.5 Policy Optimization 
In this section, the algorithm to obtain the (near) optimal polices and the extracted (near) optimal 
policies are presented. A combination of bisection and binary Particle Swarm Optimization (PSO) 
is applied to obtain near optimal policies.  
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PSO is originally attributed to Kennedy, Eberhart [33] and is a biologically-inspired algorithm 
motivated by a social analogy, such as flocking, herding, and schooling behavior in animal 
populations. The idea behind PSO is that the individuals that are part of a society hold an opinion 
that is part of a "belief space" and shared by every possible individual. Individuals may modify 
this "opinion state" based on the knowledge of the environment and the individual's previous 
history of states (its memory). For more details on PSO, please refer to [33]. 
The solutions or particles (policies) are encoded as a binary string so that a one (zero) represents 
a screening (no screening) at the corresponding age. There are two stages for the optimization 
process. In the first stage, we determine the minimum number of screening examinations (∗) 
needed to guarantee a mortality risk lower than the predefined threshold, ¿.		We use the bisection 
method and PSO to determine the optimum number of screening tests. The number of tests is 
determined based on the bisection method. For each fixed number of tests, the policy with 
minimum mortality risk is obtained using PSO. Note that, it is critical for our algorithm to 
preserve the number of screening tests when generating a new particle. Therefore, we develop a 
variant of PSO in which the number of swaps between 0’s and 1’s in a particle (solution) is the 
same (Please refer to Figure 4-8). 
In the second stage, the (near) optimal policy with the following objective function is extracted 
using a similar PSO algorithm.  
 = «¨ + ∗ ½¨ − ¿ 4-27 
In Equation 4-27, 	is the penalty for violating constraint 4-21 in the proposed model. The 
pseudocode of the bisection and particle swarm optimization is presented in Figure 4-8. Note that 
we used the (near) optimal policy found in the first stage as an input for the second stage. 
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We assume that the threshold for the mortality risk (¿ is 0.0270 (the lifetime breast cancer 
mortality risk reported by the American Cancer Society: 1 in 37 [34]). We also assume that	?y =
40, ?9 = 100, and	 = 1	year.  
4.5.1 Parameter Tuning 
The selection of PSO parameters influences the performance of the heuristic. Thus, we conduct a 
formal investigation through design of experiments (DOE) to select the best combination. 
Following is the list of parameters considered in the experimental design.  
1) Swarm size: the swarm size influences performance of PSO. Too few particles may cause 
the algorithm to get trapped in local optima, while too many particles slow down the 
algorithm. There is no exact rule in the literature for selection of swarm size. But 
generally, when dimension of the problem increases, the swarm size should also be 
increased [36]. 
2) Cognitive acceleration coefficient (Ã): this represents the weighting of the stochastic 
acceleration terms that pull particles towards	ÄÅ!, i.e., the best solution found by a 
specific particle. If the value of this constant is too high, the particles move abruptly and 
the risk of getting trapped in local optima increases. Conversely, if the value is too low, 
the particles move too slowly, and computational effort increases significantly [35]. 
3) Social acceleration coefficient (ÃT): this represents the weighting of the stochastic 
acceleration terms that pull particles towards	gÄÅ!, i.e., the best solution found. Similar 
to the cognitive acceleration coefficient, too high or too low value for this parameter can 
cause getting stuck to local optima or non-convergence of the algorithm, respectively 
[36].  
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Step 1: Bisection method and Particle Swarm Optimization El to determine Ç∗ 
procedure JEÈÃ@, ¯  ← @ + ¯2  
   While	¯ − @ ≥ 1 
       If	El	 < 	¿ then ¯ ←  
       If	El	 ≥ ¿ then 	@ ←  
  EndWhile 
end procedure 
 
procedure El 
initialization; 
   repeat     
      for i = 1 to number of individuals do 
           if  < JÈ][ −  then              	 evaluates the mortality risk (Eq. 4-21) 
                         JÈ][ −  ←   
          end if 
           if  < JÈ][ then  
                         JÈ][ ←   
          end if 
      end for 
      for i = 1 to number of individuals do 
          for d = 1 to number of dimensions do 
                Ê£[ = Ê£[ − 1 + ÃËJÈ][=@ − =@ + ÃTËTJÈ][=@ − =@ 
              R[ = Ê£[ − Ê£[ − 1 
              sort R[ according to a descending order 
              randomly choose an index  from the Max range of R[  
                 ← 1 
              randomly choose an index T from the Min range of R[ and  
                 T ← 0 
      end for 
   end for 
  until stopping criteria 
end procedure 
 
Step 2: Particle Swarm optimization ÌÍÎÏ with Ç = Ç∗ to determine the (near) optimal policy 
with the minimum overdiagnosis and a mortality risk less than ¿ ElT∗, JÈ][ is similar to El with  = «¨ + ∗ ½¨ − ¿ 
Figure  4-8 Pseudocode of the bisection and Particle Swarm Optimization methods 
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In addition, the relative value of these cognitive and social acceleration coefficients is critical 
and affects the algorithm’s performance. When the value of the cognitive acceleration coefficient 
(Ã) increases, it enhances particles’ attraction towards ÄÅ! and decreases their attraction 
towards gÄÅ!, and vice versa. In the literature, the setting of Ã = ÃT = 2	has been proposed as a 
generally acceptable setting for most problems, and is widely used in practical applications of 
PSO [35]. 
Three levels of each factors considered in the experimental design analysis are shown in Table 4-
3. A 3	factorial design is conducted. Response variables for each combination are calculated as 
the average of objective function values over all best values found by particles in the swarm. The 
algorithm performance is not sensitive to the swarm size, and does better with lower value for 
cognitive acceleration coefficient comparing to social acceleration coefficient.  
 
Table  4-3 Factorial design results 
Parameter Levels Final Selection 
Swarm size  30, 40, 50 30 
Cognitive acceleration coefficient (Ã 1, 2, 3 1 
Social acceleration coefficient (ÃT 1, 2, 3 2 
4.5.2 Optimization Results  
Table 4-4 presents the (near) optimal policies for the cases with exponential and lognormal 
sojourn time.  
For the case with the exponential sojourn time, the (near) optimal policy includes 20 
examinations	∗ = 20. The corresponding breast cancer overdiagnosis and mortality risks for 
this policy are 0.0326 and 0.0269, respectively. Note that most screenings are distributed in early 
ages (40 to 65) and there are very few tests in the interval between 66 and 74, and no tests after 
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age 74. This is due to the fact that at older ages, sojourn time is longer, and there are more aging-
related mortality causes. Therefore, from both the overdiagnosis and mortality risk perspectives, 
it is plausible to have fewer tests at older ages. Increasing the number of prescribed screenings 
yields a policy with slightly higher overdiagnosis and lower mortality risks.  
The (near) optimal policy for the case with lognormal sojourn time includes 19 screening 
tests	∗ = 19. This policy yields overdiagnosis and mortality risks of 0.0398 and 0.0269, 
respectively, which are very close to the risks of the (near) optimal policy with exponential 
sojourn time. Similar to the exponential case, most screening tests are prescribed at early ages 
(between age 40 and 65) and there is no prescribed examination after age 81.  
Note that in both exponential and lognormal sojourn time models, the (near) optimal policies 
have the same number of tests as or fewer tests than the “every three years” policy, and yet has a 
lower mortality risk and evidently lower overdiagnosis risk. Therefore, the results suggest that, 
in-practice policies with evenly distributed screening tests throughout the patient life are not 
efficient.  
Comparing the results for the exponential and lognormal cases implies that the (near) optimal 
policies follow a similar structure in both cases: more tests at younger ages and fewer tests as a 
woman ages. However, the (near) optimal policy in the case with lognormal distribution 
prescribes screenings till older ages (age 81). This is due to the increasing probability of 
instantaneous symptomatic cancer with time when the sojourn time is modeled as lognormal, as 
opposed to the constant probability of instantaneous symptomatic cancer when sojourn time is 
exponential.   
 
 94 
 
Table  4-4 (Near) optimal policies found for both exponential and lognormal sojourn time 
Age 
Exponential 
Sojourn Time  
Lognormal 
Sojourn Time Ç∗ = ÏÑ Ç∗ = ÒÓ 
40 0 1 
41 1 0 
42 1 1 
43 1 0 
44 1 1 
45 1 0 
46 1 1 
47 1 0 
48 1 1 
49 0 1 
50 1 1 
51 0 0 
52 1 0 
53 0 1 
54 1 0 
55 1 1 
56 1 0 
57 0 1 
58 1 1 
59 0 0 
60 1 0 
61 0 1 
62 1 0 
63 0 1 
64 1 0 
65 0 1 
66 1 0 
67 0 0 
68 0 1 
69 1 0 
70 0 0 
71 0 1 
72 0 0 
73 0 0 
74 1 1 
75 0 0 
76 0 0 
77 0 1 
78 0 0 
79 0 0 
80 0 0 
81 0 1 
Mortality Risk 0.0269 0.0269 
Overdiagnosis Risk 0.0326 0.0398 
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4.6 Conclusion 
Ideally, screening interventions aim to detect diseases that will ultimately cause harms, and the 
purpose of screening intervention is to advance the detection time, when the disease is in its early 
stages and is more likely to be cured. However, there is always risk of overdiagnosis and 
overtreatment when detecting a disease in its early stages. Overdiagnosis of a disease is defined 
as the diagnosis of an asymptomatic disease having no signs or symptoms, which would have 
never become symptomatic during an individual’s remaining lifetime. The fundamental idea of 
overdiagnosis is that screening intervention detects the disease at an earlier age than it would 
have been diagnosed under usual care. 
In this chapter we derive the equations for the probability of breast cancer overdiagnosis and 
mortality risks. Although applied to breast cancer, the proposed model can be generalized to 
calculate risks for any other types of cancer. We evaluate the risks associated with in-practice 
and alternative mammography screening policies recommended with different health agencies. 
The overdiagnosis and mortality risks for several in-practice policies including the ACS and the 
USPSTF policies are derived. Our estimates of the overdiagnosis and mortality risks are 
consistent with the values reported in previous studies in the literature and the derived mortality 
risk estimation based on the model proposed in Chapter 3. 
In addition, we derive the (near) optimal policies with minimum overdiagnosis risk that are 
guaranteed to have a mortality risk lower than the average breast cancer mortality risk reported 
by the American Cancer Society (1 in 37 lifetime risk of dying from breast cancer). We consider 
two possible distributions for cancer sojourn time: exponential and lognormal distributions. The 
derived (near) optimal policies mainly recommend more screenings at early ages (40-65) when 
the cancer sojourn time is shorter and the probability of dying from competing causes are lower. 
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There are more dispersed examinations after age 65, and no recommended screening after age 74 
and 81 for exponential and lognormal sojourn time, respectively. Results show that more 
efficient policies with fewer screening examinations and lower overdiagnosis and mortality risks 
than in-practice policies can be obtained. 
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 Estimation of Utilization and Usage Time of Servers Stored in a Shared Stack in an 5
Unreliable Queueing System 
5.1 Introduction 
It is very important to keep service systems operating normally in this service oriented era. 
Failing to operate a system continuously will inevitably result in waste and inefficiency, 
including downtime cost, loss of customers, and delay in providing services to customers or 
production of goods. That is the reason why preventive maintenance is of great importance in 
modem complex systems. Preventive maintenance policies enable us to reduce operating costs as 
well as the risk of breakdowns. 
In general, reliability and maintenance literature can be categorized into two broad classes: single 
component models and multi-component models. Since almost every system in the real world is 
multi-component, there has been a growing interest in the optimization of maintenance of multi-
components systems. Multi-component systems are specifically important because of the 
interactions between components in the system. These interactions between components can be 
classified into three different types: economic dependence, structural dependence, and stochastic 
dependence. Economic dependence implies that costs can be saved when several components are 
jointly maintained instead of separately (economies of scales can be obtained). Stochastic 
dependence occurs if the condition of components influences the lifetime distribution of other 
components. Structural dependence applies if components structurally form a part, so that 
maintenance of a failed component implies maintenance of working components [1]. As an 
example of economically dependent components, assume a system in which the maintenance of 
each component requires set-up work that can be shared when several components are 
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maintained simultaneously. Set-up costs can be saved when maintenance activities on different 
components are executed simultaneously, since execution of a group of activities requires only 
one set-up. This can yield considerable cost savings, and therefore, the development of 
optimization models for multiple components is an important research issue.  
In recent years, a large amount of research has been devoted to finding optimal maintenance 
policies for multi-component systems under various assumptions. Comprehensive reviews of the 
literature on maintenance of multi-component systems are given in Dekker and Wildeman [1], 
Nicolai and Dekker [2], and Wang [3]. Recently, the relatively new problem of optimal 
maintenance policies for “queues with unreliable servers” caught the interest of researchers in 
the maintenance optimization area. There are a considerable number of studies addressing the 
problem of unreliable queuing systems. However, most of these studies deal with single 
unreliable server queueing systems [4-8]. A detailed literature review on unreliable queues with 
single server was given by Choudhury and Tadj [4]. However, there are a limited number of 
studies on unreliable multi-server queueing systems. The very first study on unreliable multi-
server queues is by Mitrany and Avi-Itzhak [9].  They studied a steady-state M/M/N queuing 
system where each server is subject to random breakdowns of exponentially distributed duration. 
They derived the explicit form of moment generating function of the queue size when the 
number of servers in the system is less than 3, and proposed a numerical method for systems 
with larger number of servers.  Neuts and Lucantoni [10] studied a queue with 	identical 
servers in parallel that may break down and require repairs. They assumed that there are Ã 
repairmen in the system and the service time, time to failure and repair time are exponential. 
They derived the stationary distributions of various waiting times in the system. Wang and 
Chang [11] considered a queue with balking, reneging, and server breakdowns in which arrival, 
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service times, breakdown times and repair times of the servers are assumed to follow a negative 
exponential distribution. They developed a cost model to determine the optimum number of 
servers in the system. Wu and Ke [12] derived the necessary and sufficient condition of system 
equilibrium in an M/M/c queueing system with balking, reneging, and server breakdowns. 
Gharbi and Dutheillet [13] developed a Generalized Stochastic Petri Nets (GSPNs) model to 
analyze multi-server finite-source retrial systems with unreliable servers subject to breakdowns 
and repairs. They formulated the main stationary performance and reliability indices as a 
function of the number of servers, the size of the customer source and the stationary probabilities 
of the systems. 
There are very few papers addressing the maintenance optimization aspect in unreliable queueing 
systems. Chapin [14], in his Master’s thesis, addressed the problem of periodic replacement for a 
multi-server queueing system in which each server is subject to degradation as a function of the 
mean service rate and a stochastic and dynamic environment. Liu [15] developed a specific class 
of m-failure group replacement policy for an //Ã	queueing system where repair is started as 
soon as the number of failed machines reaches a predetermined level	. He assumed that the 
servers are unreliable with identically exponentially distributed failure times and the repair cost 
consists of a fixed cost and a variable cost proportional to the number of machines repaired. In 
addition, they assumed that there is a holding cost for each customer in the system per unit of 
time. In another study, Liu [16] developed three m-failure group maintenance models for 
//Ã	queues. The first model is the basic model with positive repair time and allows server 
failures during maintenance. The second one is a modified model with positive repair time, but 
does not allow server failures during maintenance. The last model is considering instantaneous 
repair. They proved that there exists an optimal group maintenance parameter m* which can be 
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used to find the minimal average cost for all three models. Kocuk et al. [17] studied an infinite 
server queue that is subject to randomly occurring shocks. They assumed that shocks increase the 
service time of all servers, and can cause further service deterioration. They identified the 
optimal repair rate that minimizes the expected long-run average cost incurred due to delay and 
repairs. Wu et al. [18] introduced a controllable repair policy for an infinite-capacity multi-server 
queueing system in which the servers are assumed unreliable and may fail at any time. The failed 
servers will be sent to the repair facility only when the number of failed machines in the system 
achieves a preset threshold value. They developed a cost model to determine the optimal values 
of the number of servers, service rate and repair rate simultaneously at a minimal total expected 
cost per unit time.  
The common assumption of all of these studies is that the servers (components) are operating in 
parallel and are selected randomly for service. This implies that the servers (components) are 
used in a homogeneous manner leading to independent usage and transient deterioration behavior. 
However, there exist systems in which servers (components) are not being used homogeneously. 
In such systems, some servers (components) are more likely to be used because of various 
possible reasons.  For example, the layout of the servers (components) in the system makes some 
components more accessible than others. In this case, there is stochastic dependence among 
components since the system layout and conditions of components affect the utilization and 
lifetime distributions of components.  
In 2011, Gandhi et al. [19] introduced a Most-Recently-Busy (MRB) routing policy in which an 
arriving customer is routed to the idle server that was most recently busy. Note that in a system 
with the MRB routing policy, the usage of a server is stochastically dependent on its and the 
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other servers status in the system. In this chapter, we consider a queueing system with a similar 
routing policy as MRB. In particular, we consider a queueing system with  identical servers that 
are used intermittently and, when not in use, servers are stored in a shared stack. In such cases, 
customers may find it more convenient to select the server that is on the top of the stack. 
Similarly, customers finished with a server may find it more convenient to place the server back 
to the top of the stack. As a result, servers that begin at or near the top of the stack are used more 
frequently than the servers that are placed lower in the stack. In such a system, a server’s 
utilization is stochastically dependent on its initial location in the stack and the usage of the other 
servers.  Note that although we consider a queueing system with stacked servers, the outcomes of 
this study are applicable to any queuing systems with the MRB routing policy.  
An everyday example of a queueing system with stacked servers or MRB routing policy is a set 
of shopping carts in a retail store. Often, shopping carts (the servers in this example) are arranged 
in stacks, so that the customers typically choose the cart at the front (the top in this example) of 
the stack. After usage, carts are often returned at or near the front of the stack.  
The goal of this study is to compute the cumulative, transient utilization and usage time of a 
server as well as the expected complete reshuffling time in such a queuing system based on the 
number of servers in the stack, the initial position of the server in the stack, and the arrival and 
service rates. The expected complete reshuffling time is defined as the minimum time it takes for 
all the servers in the system to be used. We assume that the servers are identical and numbered 
based on their initial position in the stack. We also assume that the demand for servers occurs 
according to a Poisson process and the duration of a single service instance follows an 
exponential distribution. Customers arriving to a full system balk. This study provides a tool to 
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investigate the utilization and aging patterns of components in such a system. The outcomes of 
this study can assist decision makers to have an accurate estimate on the deterioration behavior 
of components in such a system, and thus maintain a more effective maintenance policy for 
components and have a more robust estimate of reliability measure of such systems.  
The remainder of this chapter is organized as follows. In Section 5.2, the proposed continuous-
time Markov chain model is presented. Section 5.3 presents the computational results. Finally, 
Section 5.4 summarizes the findings and discusses future directions.  
5.2 Proposed Model 
Consider a queueing system with  identical servers stored in a stack. Let server 	 =
1, 2, … ,  be the server whose initial position in the stack is . We develop a continuous-time 
Markov chain (CTMC) model to compute the cumulative, transient utilization, and usage time of 
server  and the expected reshuffling time of the system. The states of the system are represented 
by Ö[ = , Z, where  ∈ {0, 1, … , } represents the server’s position in the stack and 
Z ∈ {0, 1, 2, … , }  represents the total number of busy servers at time	[. For the first element of 
the states  = 0 represents the situation when the server is busy and is not stored in the stack, 
and	 = 	 = 1, 2, … , ) represents the situation when the server is stored in the !" position 
in the stack. Note that in the remainder of this chapter, the !"server refers to the server with 
initial position  in the system. We assume that at time zero the system is empty, i.e., Ö[ = 0 =
, 0. The total number of states in the proposed CTMC is	 = 66T + . Figure 5-1 shows the 
transition diagram of the system along with the transition rates.  
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Figure  5-1 Transition diagram of the proposed Markov chain model 
5.2.1 Servers’ Utilization and Usage Time 
Let	×6 be the “in use” set, or the set of states in which the server is busy when there are  servers 
in the system (the states in the first row of the transition diagram in Figure 5-1). 
×6 = {0, ,  = 1, 2, … , } 
Let Ø6[ be the utilization of the server up to time 	[. Ø6[	is the proportion of time that the 
server is in the “in use” set, or set ×6, when starting from state , 0, as defined in Equation (5-1)  
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Ø6[ = ∑ ,y,[∈ÜÝ [ , 5-1 
where ,y,[ is the occupancy time of  state ] up to time [ when starting from state , 0, and 
is calculated as  
,y,[ =  ,yÊÊ,!y  5-2 
where ,yÊ is the transition probability from state , 0 to state ] at time Ê. ,yÊ	can be 
calculated using different methods: e.g., Chapman-Kolmogrov equations, Laplace transform and 
eigenvalue decomposition of the infinitesimal generator matrix s	of the CTMC model [20]. In 
eigenvalue decomposition method, the transition probability matrix of a CTMC with 
infinitesimal generator matrix s is given by  
[ = ÖÈÞ!Ö, 5-3 
where F is a diagonal matrix for which the elements on the diagonal are the eigenvalues of 
matrix s, and Ö is an invertible matrix whose columns are the eigenvectors of matrix s. 
 
Note that since we consider balking in our queuing system, the effective arrival rate of the 
system is 	ßÄ = 1 − Ä ∙ ß, where Ä is the probability that an arriving customer balks and is 
presented in Equation 5-4.  
Ä = lim!→ y,6	[, ∀] 5-4 
Therefore, as shown in Equation 5-5, the server’s long run utilization is	áâ6ã, which is smaller than 
the stationary utilization level in a non-balking system. That is,  
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lim!→Ø6[ = áâ6ã < á6ã. 5-5 
A main characteristic of the system that is critical in identifying an optimal maintenance policy is 
a server’s age at time	[. To model the deterioration pattern and failure probabilities of the servers, 
it is critical to know for how long a server has been used in the system. The usage time of a 
server i is the area under the utilization curve up to time	[, as presented in Equation 5-6. 
A6[ =  Ø6ÊdÊ!y  5-6 
 
5.2.2 Complete Reshuffling Time 
Reshuffling time of the first 	servers in the stack is defined as the time it takes for the system to 
use the server with initial position  in the stack for the first time. Equivalently, reshuffling time 
of the first 	servers is the first passage time to state 0,  in the proposed Markov model.  We 
specifically are interested in the “complete reshuffling time” which is the time that it takes for 
the system to have a complete reshuffling of all servers in the stack, or the time to hit state 0,  
in the model for the first time. This measure is important since once we have a complete 
reshuffling, all servers become identical from that point forward. In other words, the transient 
effect of their starting positions in the stack is effectively over. 
Let T  be the time to visit state	]′ for the first time when starting from state	]. Reshuffling time 
of the first  servers in the system or time to visit state 0,  for the first time is defined in 
Equation 5-7.  
\,yy, ≡ min{[ ≥ 0	|Ö[ = 0, , 	Ö0 = , 0} ,  = 1, 2, … ,  5-7 
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Note that the reshuffling time is independent of 	(the initial position of the server in the system) 
since we assume that the system is empty at time [ = 0.  
Let  be the expected first passage time to state 0, 	when starting from state ], i.e.,   
 = è,\y,6/. 5-8 
Then  = [, T, … ]′ can be calculated by solving this system of equations  
 + Ò = 0, 5-9 
where  is obtained by deleting the row and column corresponding to state 0,  in matrix s 
[20].  Note that when ] = , 0,  = 1, 2, … , , the corresponding value  presents the expected 
complete reshuffling time. 
5.3 Numerical Examples 
This section illustrates the cumulative transient utilization, virtual age and complete reshuffling 
time for different queuing systems. Note that in all numerical examples without loss of generality 
we assume that	é = 1.  
Figures 5-2 and 5-3 present the utilization and usage time plots for all servers in the stack along 
with the expected complete reshuffling time for a queueing system with  = 3 servers and 
arrival rates	ß = 0.25, and		ß = 1, respectively.  
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a) Usage time (ß = 0.25 
 
 
 
b) Utilization (ß = 0.25 
 
 
Figure  5-2 a) Usage time and b) utilization of servers in a queuing system with  = 3 and arrival 
rate 0.25 
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a) Usage time (ß = 1 
 
 
 
b) Utilization (ß = 1 
 
 
Figure  5-3 a) Usage time and b) utilization of servers in a queuing system with  = 3 and arrival 
rate 1 
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The corresponding balking probabilities for the two different arrival rates are	0.002, and 0.062, 
respectively.  The horizontal dark gray lines in the utilization plots show the servers’ stationary 
utilization in a non-balking system, which, as expected, is larger than the servers’ stationary 
utilization in the system under study. Note that in the first case where λ= 0.25, the system has 
not yet reached the steady state after 1000 time units and it has a significantly longer mean 
complete reshuffling time than the case with arrival rate λ= 1	(188 time units versus 8	for the 
second case).   
Figures 5-4 to 5-6 present the results for a queueing system with  = 10 servers and arrival rates 
λ= 1, λ = 2, and	λ = 3 for the first 5000 time units, respectively. For none of the cases, the 
system has reached the steady state after 5000 unites of time. All the three cases have negligible 
balking probabilities. The complete reshuffling times for these cases are 1,112,083, 3,410.56, 
and 192.94, respectively. Note that for the first case with ß = 1	at time	[ = 5,000, the ages of the 
first four servers in the stack are over 800 each. However, the last two servers in the stack have 
not been used yet. In the case with	ß = 3, however, the servers have a more consistent aging 
pattern. 
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a) Usage time (ß = 1 
 
 
 
b) Utilization (ß = 1 
 
 
Figure  5-4 a) Usage time and b) utilization of servers in a queuing system with  = 10 and 
arrival rate 1 
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a) Usage time (ß = 2 
 
 
 
b) Utilization (ß = 2 
 
 
Figure  5-5 a) Usage time and b) utilization of servers in a queuing system with  = 10 and 
arrival rate 2 
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a) Usage time (ß = 3 
 
 
 
b) Utilization (ß = 3 
 
 
Figure  5-6 a) Usage time and b) utilization of servers in a queuing system with  = 10 and 
arrival rate 3 
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5.4 Conclusion 
All the previous studies on unreliable multi-server queuing systems assume that servers’ 
utilizations are independent from each other and an arriving customer selects one of the available 
servers randomly. However, there exist systems in which the customers routing pattern is non-
random and customers select a server according to a defined pattern. An example of a non-
random routing policy is the Most Recently Busy (MRB) policy, in which an arriving customer 
selects the idle server that was the most recently busy.  
In this chapter, we considered an unreliable queuing system with the MRB routing policy. In 
particular, we considered a queueing system for which the servers are stored in a stack when they 
are not in use. In such systems, an arriving customer picks the idle servers on the top of the stack 
for service. Similarly, when the service is over, the server is returned to the top of the stack. In 
such a system servers have heterogeneous utilization and deterioration behaviors because of the 
stochastic dependence of a server usage on its position in the stack and the utilization of the other 
servers in the system. 
To maintain such systems more effectively, the decision maker needs to have an understanding 
of the utilization behavior and deterioration pattern of each server in the system. In this chapter 
we proposed a model to characterize and quantify the critical feature in estimating the 
deterioration of each server. We developed a continues-time Markov chain (CTMC) model to 
measure the transient utilization and usage time of each server based on the initial position of the 
server, the arrival rate and the service rate in the system. We also proposed a formula to compute 
the system’s expected complete reshuffling time, i.e., the expected time to use the last server in 
the stack for the first time. This measure is of interest since when the last server in the stack is 
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used for the first time, all servers become identical in terms of their possible position in the stack 
from that point on. 
This study provides insight to the decision maker to have a more efficient maintenance policy for 
a queueing system with the MRB routing policy, or more specifically a queueing system with 
stacked servers. The model presented in this study helps the decision maker to effectively 
estimate the viral age of each server in the system, and accordingly approximate the deterioration 
of a specific server and derive the optimal maintenance policy based on the estimated 
deterioration.  
A future direction for this research is to study different individual and group maintenance 
policies such as age replacement, block replacement, –failure, or policy ( − \ policy (the 
combination of block replacement and	–failure policy) , and perform a cost analysis to derive 
the optimal maintenance policy for such systems.  
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